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Clinical Trial Classification Problem (CTCP) is one of the cutting-edge real life applica-
tions in medicine.
The system described in this thesis aims to induce a classification model by Clinical
Trials (CT) XML structured data in order to find a model that predicts patient’s pro-
file for eligibility criteria in breast cancer CT. Remarkably, the task considered in this
work has been oriented to prediction of both Eastern Oncology Group (ECOG) and
Karnofsky (KPS) scales. This scales represent the stage of the cancer disease patient
suffers in order to be eligible to participate in the trial.
This particular task of CS comprise the use of Natural Language Processing (NLP) and
Machine Learning (ML) techniques, which are two of the emerging areas of CS sub-
field’s, Artificial Intelligence (AI).
NLP has become one of the most important areas of AI due to its interesting cutting-
edge applications in real life as Textual Document Processing, Automatic Summariza-
tion, Machine Translation, Sentiment Analysis, and many others.
Besides the great success NLP has achieved in big trendy and commercial appli-
cations now days, it has also been used to solve general text understanding tasks
as Natural Language Understanding, Natural Language Generation, Information Retrieval
and Text Mining, having a relevant impact in different real life fields such as Politics,
Medicine, Finances, Governmental Security, Commerce, and Psychology.
Furthermore, ML an important branch of AI, comprise algorithms such as Neural
Networks (NN), Support Vector Machines (SVM), Ensemble Methods (EM) that are based
on data statistical learning. These methodologies have become meaningful to solve
real-life classification and regression tasks. According to literature, Non-Linear mod-
els are suitable for complex tasks as Speech Recognition, Drug-Drug Interaction Predic-
tion, Twitter Sentiment Analysis and Clinical Trial ECOG-Classification and instance of
CTCP. On the other hand, Linear models are robust enough at applications as Stock
Market Trend Prediction.
Clinical Trial ECOG-Classification (CTEC) is considered a computational task related
to the decision support Systems utility. The task has a considerable importance in
the field of medicine, in particular on the oncology department at breast cancer re-
searching.
All this seems to be more workload than what the daily shift of an oncologist will
allow. For this reason, a good approximation of an accurate decision support system
that will help to asses the annotation of new breast cancer treatments patient’s pro-
file.
Consequently, this application as complementary support decision tool will help
physicians to do work in parallel saving time at reviewing new extensive CT files.
This may only require cancer specialist’s custom-periodical reviews of the decision
support model in order to validate the accuracy and performance.
Moreover, CTEC presents a high degree of difficulty in terms of the NLP and ML
subtasks required for this application. Related to the NLP computational aspect,
difficulties rely under the localization, classification and disambiguation of medi-
cal Name Entities such as: disorders, diseases, drugs, body parts, medical signs, etc.
Furthermore, extraction of medical text related to measures, dose, units, etc. is also
challenging. All these issues in Electronic Health Records (EHR) and CT have their
origin on highly ambiguous acronyms and abbreviations, and on highly ambiguity
of medical jargon. Professionals and technicians writing at the oncology department
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and pharmaceutical research centers cause these language difficulties.
After described briefly, the AI trends and the CTEC application relevance and dif-
ficulty, let us describe technical aspects related to the problem. The data comprises
8,594 CT XML files related to different breast cancer treatments from all countries
around the world. This information was retrieved from clinicaltrials.gov considered
as the biggest and most popular source of trials data freely available in the medical
scope.
Breast cancer CT treatments contain a relevant attribute, eligibility criteria that con-
siders the stage of cancer in patient’s condition in terms of a PS scale scoring. Most of
the CT have an explicit PS scoring range on different breast cancer PS scales (ECOG,
KPS). This particular application considers extraction of discriminant features and
extraction of the PS scale scores to compose predictors and response variables of the
training set.
As it was previously mentioned, the CS application requires extracting PS scale
scores to compose response variables in training set by finding numerical patterns
at eligibility criteria textual field. Moreover, the application requires extracting dis-
criminant features from breast cancer CT eligibility criteria and consequently after
both extractions builds a training set. After that, some additional processes have to
be performed to data as data projections, removing noise, removing non-statistically
representative samples, predictions refining, etc. All this in order to find the most
suitable representation of the training set.
Consequently, after shaping up the data, the next step considers statistical model
building, particularly to classify or predict the most suitable ECOG-KPS patient’s
profile. This profile, as previously mentioned resembles the participant profile based
on their physical daily activity that constrains the application of participants for a
new breast cancer treatment under clinical testing. The accurate prediction of this
profile will result in avoiding misclassification assignments to trials and potential
drug-side effects to patients.
In brief, the motivation of this project is selecting most suitable NLP and ML method-
ologies to minimize generalization error prediction i.e. increase prediction robust-
ness over new CT samples.
Therefore, a robust model main advantage relies on finding the appropriate patient’s
profile for every breast cancer treatment and consequently reduces potential drug-
side effects or health complications.
Further expectations are focused on development of a profitable software frame-
work as complementary support medical system that may be used as a software tool
for medical institutions and experts in the area, boosting the loads of work among
the new breast cancer treatments profiling.
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1Chapter 1
Introduction
1.1 Context
Clinical Trial Classification Problem (CTCP) is one of the cutting-edge real life applica-
tions in Medicine by the use of Computer Science (CS) methodologies.
The application presented in this thesis aims to induce a classification model that
discriminates patient’s profile in Breast Cancer Clinical Trials (CT). The task consid-
ered in this work has been implemented as a multivariate regression predicting CT
ECOG and KPS min/max scores.
This particular task of CS comprises the use of Natural Language Processing (NLP)
and Machine Learning (ML) techniques, which are two of the emerging areas of CS
subfield’s, Artificial Intelligence (AI).
Medical informatics has gained relevance with the pass of the time through real life
applications. All these applications are categorized by different utilities in medicine
such as: clinical decision support, medical and pharmaceutical time line analysis,
underlying patterns in medical entities relations, and many others.
For instance, clinical decision support system implementations [30] aim to aid deci-
sion making of health care providers and the public by providing easily accessible
health-related information at the point and time it is needed. Moreover, medical
and pharmaceutical reports time line analysis [10] purse to identify the temporal re-
lations between clinical events and temporal expressions as Admission Date, History
of Present Illness, Hospital Course, and Discharge Date in clinical reports. Addition-
ally, Underlying patterns in medical entities relations [8] intend to find relationships
among medical entities previously annotated and consequently asses relevance scor-
ing among them. This application scope comprise different stages such as: Semantic
Tagging of Medical Categories, Relation Extraction in the Medical Domain, Ontology Met-
rics in the Medical Domain.
Clinical Trial ECOG-Classification (CTEC) is considered a computational task related
to the decision support systems utility type. Besides, the task has a considerable
importance in the field of medicine, in particular on the oncology department at
breast cancer researching. For this reason, the application has an important value as
a decision support system for physicians in charge of breast cancer condition. The
utility of the software application considers the following scenario at physician’s
daily loads:
• Oncologist load of work at daily schedule.
• Emergency department institutional prompts.
• Oncology department patient’s follow up.
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• CT pharmaceutical researching collaborations and design.
All this seems to be more workload than what the daily shift of an oncologist will
allow. For this reason, a good approximation of an accurate decision support sys-
tem that will help to asses the annotation of new breast cancer treatments patient’s
profile. Prediction of the scores related to patient’s profile could be oriented in ei-
ther ECOG or KPS scales. Consequently, this complementary support decision tool
will help physicians to do work in parallel saving time at reviewing new extensive
CT files. This may only require cancer specialist’s custom-periodical reviews of the
decision support model in order to validate the accuracy and performance. Despite
the availability of a huge amount of CT reports, as shown in Table 2.1, Table 2.2,
Table 2.3, and many of the documents lack ECOG or KPS scale information. So, it is
important to enrich the document with an estimation of these scores.
Moreover, CTEC has certain degree of difficulty in terms of the NLP and ML tasks
required for this application. Related to the NLP computational aspect, difficulties
rely on the localization, classification and disambiguation of medical Name Entities
(NE) such as: disorders, diseases, drugs, body parts, medical signs, etc. Further-
more, NLP aspects have certain percentage of difficulty at extracting medical text
related to measures, doses, units, etc. All these NLP medical text issues in Electronic
Health Records (EHR) and Clinical Trials (CT) have their origin on highly ambiguous
acronyms and abbreviations, and on high ambiguity of medical jargon. Interest-
ingly, different professionals and technicians writing at the oncology department
and pharmaceutical research centers cause these language difficulties. Furthermore,
issues on the ML subtasks are related to the learning itself of the model that will rep-
resent the CT - ECOG/KPS profiles accurately considering the most representative
clinical text features or a combination among them together with an encoded repre-
sentation of variable ranges associated to each CT. Therefore, finding a model that is
able to predict or classify an ECOG or KPS profile, has to find a proper representa-
tion of the data. Moreover, a model itself has it’s own intrinsic way of representing
data (e.g. linear or non-linear), a complexity in terms of computational resources
and own ways to penalize a high variance over the training CT samples. For this
reason finding a proper representation of the data and a good approximation of an
optimum configuration of model is not an easy task.
In essence, the motivation of this project is selecting most suitable NLP and ML
methodologies and tools to minimize generalization error prediction i.e. increase
prediction robustness over new CT samples. Therefore, a robust model main ad-
vantage relies on finding the appropriate patient’s profile for every breast cancer
treatment and consequently reduces potential drug-side effects or health compli-
cations. Further expectations are focused on development of a profitable software
framework as complementary support medical system that may be used as a soft-
ware tool for medical institutions and experts in the area, boosting the loads of work
among the new breast cancer treatments profiling’s.
In recent years NLP has become one of the most relevant areas of AI by it’s inter-
esting cutting-edge applications in real life as Textual Document Processing, Automatic
Summarization, Machine Translation, Sentiment Analysis, and many others. Besides
the great success NLP has achieved in big trendy and commercial applications now
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days, it has also been used to solve general text understanding tasks as Natural Lan-
guage Understanding, Natural Language Generation, Information Retrieval and Text Min-
ing. Hence, general tasks applications in NLP require low-level NLP subtasks:
• Localization and Extraction of Textual Content.
• Text Cleansing.
• Language Identification.
• Sentence Splitting.
• Tokenization.
• Stemming.
• Lemmatization.
• Morphological Analysis, including the normalization of dates, formulas, quantities,
and units.
• Named Entity Recognition (NER).
• Part Of Speech (POS) tagging.
• Lexical Analysis.
• Syntactic Analysis.
• Semantic Analysis.
The application of these NLP functionalities have been impacted in meaningful ap-
plications among different life fields such as Medicine, Finances, Politics, Governmental
Security, Commerce, and Psychology.
Furthermore, another popular AI branch, ML, aims to mimic the behavior of life
phenomena’s by building models for certain life processes based on data (observa-
tions). This recently applied area comprises algorithms that learn to either discrim-
inate or predict in different ways how life phenomena’s will conduct from a given
input. Every ML algorithm is featured by:
• A learning approach: Supervised, Semi-Supervised, Unsupervised, or Reinforced.
• A learning task: Classification, Regression, or Ranking.
• A learning complexity: Linear or Non-Linear.
• A learning outcome: Mono, Binary or Multiple.
The most popular ML algorithms in terms of the number of applications registered
in literature are: Artificial Neural Networks, Support Vector Machines, Conditional Ran-
dom Fields, Maximum Entropy (also named Logistic Regression), Bayesian Networks, and
Ensemble Methods. These methodologies have become meaningful to solve many of
the real-life classification and regression tasks from the literature. Moreover, some of
them are suitable for particular type of problems. According to literature, Non-Linear
models are suitable for complex tasks as Speech Recognition, Drug-Drug Interaction
Prediction, Twitter Sentiment Analysis and Clinical Trial ECOG-Classification. On the
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other hand, Linear models are robust enough at applications as Stock Market Trend
Prediction.
After a brief description of the AI methodologies deployed in this work, let us de-
scribe briefly the theoretical aspects of the CTCP and a simple description of the
medical terms related to this application.
According to [28], Clinical Trial (CT) is research study that aims to analyze the effec-
tiveness and safeness of drugs, strategies and devices applied in human health treat-
ments. Moreover, it is considered an instrument to establish comparisons among
different medical procedures to find the most suitable option for a particular disease
or people’s physical condition. Consequently, these analysis outputs are meaningful
observations used to perform automatic decision making as complementary tools in
the medical sector. CT data are obtained as a result of a strict research and collection
methodology process, which involves the following stages:
1. Laboratory Design.
2. In-Silico Analysis.
3. In-Vitro Analysis.
4. In-Vivo Analysis: Animal Testing.
5. In-Vivo Analysis: Human Testing.
6. Outcome Interpretation.
There are different type of CT for different diseases and different treatments, how-
ever in this work, we strictly focus on CT Breast Cancer. Based on [9], CT in breast
cancer are the safest and less invasive way to understand the disease for prevention
and survival purposes. These types of CT are regulated by The US Food and Drug Ad-
ministration (FDA), an organization that aims to asses and approve new treatments
as routine care in patients. The breast cancer CT and trials in general follow a rigor-
ous study protocol. Besides, in some cases drug treatment proposals are constrained
to different types of cancer drugs and others to potential combinations of drugs and
procedures. Furthermore, before breast cancer CT results are analyzed, The Human
Testing is conducted through Phases from 1-4, in which the number of people, and
the complexity of the treatment is incremental at each stage until FDA approves the
study (in case of the USA) and a consequent follow up is performed.
According to [14], researchers have found that in order to be able to conduct trials
in a consistent way across all the research centers, hospitals and institutions they
require a standard metric that asses the daily physical activities of a patient. This
standard metric is known by researchers as Performance Status (PS) represented as
a numeric scale, which tracks the profile of patients participating and asses their
evolution through the experiment. However, performance status has been evaluated
through the following different scales:
• Eastern Oncology Cooperative Group (ECOG).
• Karnofsky (KPS).
• Lansky (LKS).
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According to [41] ECOG scale was published by the American Oncologist Charles Gor-
don Zubrod and The Eastern Cooperative Oncology Group in 1982. This scale is also
known as WHO or Zubrod and it comprises a range between 0 and 5, denoting 0 as
a fully active pre-disease stage and 5 as death. Besides, this scale circulates and it
is available at the public domain, and moreover, considered as future reference and
further standardization criteria to assess functionality status of a patient. The main
reason of this relies on the simplicity of the scale compared to other performance
status scales.
Furthermore, another relevant scale is KPS [22], a PS scale that was published at first
in literature by the American Oncologist David Aryah Karnofsky in 1948. The scale
index ranges between 0 and 100, where 0 denote death and 100 normal activity mi-
nor signs of disease. The KPS scale main concern was the evaluation of patient’s
survival ability to chemotherapy.
Additionally, there is a third scale from the most well known scales, LKS perfor-
mance status, which is consistently similar to KPS. The main difference relies in LKS
main usage, as children quality observational scoring approximate system and as-
sessing tool when an impediment of children to express their life quality exists.
The following table represents the equivalence among the different performance sta-
tus scales scores, and a general description of each score. However, since the scoring
and description of Karnofsky and Lansky scales are similar, we only consider com-
parisons among ECOG and KPS scales.
ECOG scoring KPS scoring Patients Profile Description
0 100 Normal, no evidence of disease.
90 Normal activity, minor symptoms.
1 80 Effort required, some symptoms.
70 Unable to perform active work.
2 60 Occasional assistance required.
50 Considerable assistance required.
3 40 Disable, special care required.
30 Severely disable, hospitalization indicated.
4 20 Very ill, hospitalization required.
10 Moribund.
5 0 Dead.
TABLE 1.1: ECOG-KPS equivalences and patients profile description.
Consequently, after a wrap up of a detailed description related to the task’s back-
ground considered in this work, the application relevance, and intrinsic and poten-
tial difficulties of the task, let us describe the basic technical aspects of the software
implementation. The instance of the CTCP considered in this work was based from
a Stack Overflow Careers job posting. Indeed, this document was distributed freely
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among the candidates that applied for the data scientist position at MedBravo med-
ical research center based in Barcelona. The implementation of the task [26] consists
in applying NLP techniques over breast cancer CT Dataset retrieved from [11]. The
task comprises a parsing ECOG scoring and a extraction of meaningful features from
the clinical text of each file in order to build a training set. Therefore, after having
a clean and representative dataset, the next step consists in deploying ML method-
ologies to build a good approximation of an optimum statistical model. After that,
there is an implementation stage to classify the most suitable ECOG scoring ranges
among testing set samples, where each sample is represented by a numerical vector,
related to the relevance most representative terms from set of CT XML files. Besides,
the sample class, which represents a range of classes, is represented as min and max
scores from the range of classes assuming a consecutive multi class range.
1.2 Contributions
• Software Development1. ECOG range-scoring XML CT extraction. This module
implements complex regular expressions and ECOG-KPS equivalence conver-
sions.
• Software Development. Cleansing, Tokenization, Stemming, Bag Of Words, and
Feature Extraction over CT. This module perform over all CT CORPUS, cleans-
ing and extracting relevant features known as Bag Of Words from XML CT
files.
• Software Development. Machine Learning Regression-Classification Framework.
This module implements the most robust multi-regression and multi-classification,
linear and non-linear models.
• Software Development. Score Distribution, Prediction, and Aggregation Plot Frame-
work.
• Proposal of a suitable Text Vectorization, Data Projections, Prediction Refining, Re-
moval of Problematic Cases, and Model Section for a ECOG/KPS CT Breast Cancer
Patient’s Profile Prediction.
1.3 Guideline
The document organization starts with Chapter 1, a brief introduction to a first insight
of the work done in this thesis, this section additionally contain aspects as medical
context foundations, project aims and goals, and contributions done to the medical
application. After that, Chapter 2 describes the computational and technical aspects
of the task in terms of NLP and ML notions as a problem modeling. Additionally,
we follow up with Chapter 3, a state of the art, in which we intend to grasp a wide
panorama of the previous work done related closely to the application task of this
project. Moreover, we continue with Chapter 4 describing the experiments done with
data representations, predictions refining, and model tuning in order to boost learn-
ing in predictions. After that, we present in closing results in a brief and a proper
way in Chapter 5. To sum up, in Chapter 6, we established a conclusion of the exper-
imental results obtained by the experimentation done in Chapter 4, we summarized
all the work done, work trade-offs, and potential improvements as future work.
1Most of the developments have been done in Python, using specific modules for NLP and ML.
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Clinical Trial Classification
Problem
2.1 Definition
As it has been mentioned in the previous chapter, breast cancer CT is a meaning-
ful instrument that aims to analyze both the effectiveness and safeness of health
treatments. This instrument also assesses strategies and devices related to patient’s
health care presenting breast cancer condition.
Additionally, as it was previously stated, PS is considered as the standardized met-
ric to asses CT, track patient’s treatment evolution and unifies researching analysis
through different institutions and countries.
However, PS can be represented by different scales: ECOG, KPS, and LKS. These
scales describe the stage of cancer based on the daily physical activity of the pa-
tients.
Therefore, we are going to consider the ECOG scoring from the scales mentioned,
since it is the most standardized scale world wide for Non Neuro-oncological dis-
eases. Furthermore, even if KPS scale is not the most standard metric it provides a
wider range compared to ECOG and consequently more precision. For this reason
we are going to consider the usage of KPS in experiments as a potential prediction
advantage.
Moreover, related to the type of problem originally considered in this work, which
was originally purposed as a multi-output and multi-label classification task type.
After some approach discussions, we agreed to follow the respective wrap up adap-
tations:
• Consecutive numeric stages in PS scales.
• Prediction model seen multivariate regression, predicting min and max PS scale
bounds in the range.
According to the generic NLP subtasks list included in Chapter 1: Section 1, task
considered in this work comprise the following stages:
1. XML Data Acquisition.
2. ECOG scoring extraction (obviously in the case the score occurs explicitly in
the text).
3. Data Cleansing.
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4. Bag Of Words Construction.
5. Eligibility Criteria Text Vectorization.
6. SVD Data Projections.
7. Machine Learning Multivariate Regression.
8. Machine Learning Algorithms Tuning.
Before getting into task technical details, we proceed with proper reference to the
data retrieved from clinicaltrials.gov. This data source is considered by medical pro-
fessionals the biggest and most popular source of trials data freely available.
In order to reference this source, we are going to describe the data distributional
aspects of the research scope retrieved by clinicaltrials.gov updated by March 2018:
• Distribution of the CT research approached by U.S. and other countries, shown
in Table 2.1.
• Distribution of CT researching on breast cancer is performed by the U.S. and
other countries, shown in Table 2.2.
• Distribution of the breast cancer study types considering CT from all the coun-
tries all over the world, shown in Table 2.3.
Country Registered Recruiting
U.S. only 95,265 17,702
Non-U.S. only 127,689 26,671
U.S. & Non-U.S. 14,615 2,390
Not provided 32,031 57
Total 269,600 46,820
TABLE 2.1: Registered and Recruiting General Clinical Trial Statistics.
Country Cancer Breast
Cancer
U.S. only 31,268 4,316
Non-U.S. only 29,544 3,791
Total 60,812 8,107
TABLE 2.2: Cancer and Breast Cancer Clinical Trial Statistics.
To begin description with, the dataset [11] comprises 8,594 CT XML files related to
different breast cancer treatments. For clarification purposes, let us mention that the
8,594 CT comprise the union of the unique 8,107 + 487 samples of the current data
obtained by late March, 2018 and CT studies obtained at late May, 2015 that were re-
moved on-line recently. Furthermore, for the sake of clarification purposes, there are
4,023 CT samples that contain PS KPS/ECOG scores in eligibility criteria CT XML
field.
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Study Type Registered
Studies
Studies
w/Results
Interventional 6,573 866
Observational 1,515 46
Expanded Access 15 N/A
Total 8,107 912
TABLE 2.3: Breast Cancer (All Countries) Studies Types: Interven-
tional, Observational, and Expanded Access in Clinical Trial Statis-
tics.
Breast cancer CT treatments contain a eligibility criteria attribute, which considers
the stage of cancer in patient’s condition in terms of a PS scale scoring. Eligibility
criteria is described in textual form but frequently includes explicitly the PS scoring.
More details about the content of Eligibility criteria can be found in Section
2.2 Clinical Trial Fields
. This score ranges on different breast cancer PS scales (ECOG, KPS, LKS), and syn-
onyms of them. However, the multivariate regression problem will focus on ECOG
scale since most of the researchers consider it as an standard metric for Non Neuro-
oncological type of cancer as breast cancer. Even though, KPS scoring is considered
in the first stage of scoring extraction due its precise scale, so after predictions are
obtained, there will be an equivalence stage to retrieve ECOG scores. Examples of
an XML file with an explicit and non-explicit scoring can be found in Appendix A.
Furthermore, for this particular application we considered eligibility criteria field
as the most relevant source for feature extraction based on the original requirements
from [26]. Therefore, in this research we have used eligibility criteria as the clinical
text source to build BOW.
Besides Eligibility Criteria, there other fields in the XML CT as Brief Description, Title,
and many others that may have key discriminant information that can be extracted
as potential features for boosting model learning.
2.3 Clinical Trial Scoring Distribution
The instance of the breast cancer CTCP considered in this work has a higher mod-
eling complexity due to it’s type of task and outcome. This particular instance of
CTCP is featured by Multi Label and Multi Output in a classification learning type.
This fact assumes that more than one class (PS cancer stage) can be present on CT
participant’s profile eligibility.
For this reason, we proceed modeling the task as a Multivariate Regression simplify-
ing model complexity by its numerical label nature, considering two scores to learn
min and max representing the CT PS range bounds.
In order to overview the scoring frequency distribution we performed one of the
NLP generic subtasks Regular Expressions (RE). RE were used to extract numerical
scoring of PS scales from CT with an explicit scoring PS, keeping only the min and
max values from the range.
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Plots in Figures 2.1, 2.2, and 2.3 describe the frequency distribution of the range
min-score, max-score, and range-size of all CT samples in CORPUS:
FIGURE 2.1: Min scoring distribution from KPS samples range.
FIGURE 2.2: Max scoring distribution from KPS samples range.
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FIGURE 2.3: Range size (Max-Min) distribution from KPS samples.
As we can observe, breast cancer CT data for this particular annotation task seem to
be class-unbalanced. We based this assumption on the data scorings reflected on the
plots, this fact might be reflected as a higher complexity at model learning.
2.4 Clinical Trial Fields
CT reports are indented for human use, and, so, most of their content is textual. For
this reason most of the features used for learning the models consists of words oc-
curring in the document, regardless the order of occurrence, and the specific field
where they occur. This model for representing the document is usually named a Bag
of Words (BOW)1. Moreover, CT XML files are composed of different attributes or
fields with information related to data source, sponsors, study summary, study out-
comes, observations, eligibility criteria, study affiliations, location, and many others.
However, the number of attributes contained in the CT vary based on the study and
can be up to 60 different fields (leaves in the XML tree structure).
However, for this particular application we selected Eligibility Criteria field as BOW
terms source by its direct relation describing the type of patient’s profile that can be
eligible as candidate in a numerical or textual way. Besides we considered this field
for being consistent with the original task proposed by [26].
Furthermore, as future work we will be open to consider other relevant fields, which
provide discriminant information for patient’s profiling. For instance, CT XML fields
as locations, affiliations do not provide any discriminant information to compose a
BOW and consequently build a representative data set. Ideally, after performing a
visual inspection of the attributes of XML files, we found that following XML fields
may be considered as potential candidates of BOW source in further stages of the
1Other related forms of representation are Bag of lemmas, Bag of words+POS, bag of stems, and
bag of n-grams
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project. For sake of clarification, technical definitions are referenced by the Clinical-
Trials.gov - Protocol Registration Data Element Definitions for Interventional and Observa-
tional Studies [31].
• eligibility_criteria: a plain text limited to 15,000 characters, which is denoted
by a selection criteria list to filter participants in the clinical study. This list pro-
vided information in terms of inclusion and exclusion criteria and suitable for
assisting potential participants in identifying clinical studies of interest. Re-
markably, this items list includes both textual and non-textual information (as
the age, and ECOG or KPS scores).
• brief_summary: plain text limited to 5,000 characters that describe a short ti-
tle of the clinical study written for public distribution and understanding. This
attribute should include information of the participants, conditions being eval-
uated, and interventions studied.
• detailed_description: a plain text limited to 32,000 characters, in which there
is an extended description of the protocol, including more technical aspects
compared to Brief Summary field. However, this field do not include the entire
protocol and neither duplicate information recorded in other data elements as
Eligibility Criteria.
• brief_title: plain text limited to 300 characters describing a short title of the
clinical study in a public divulgation jargon. This attribute should include
patient’s information, condition being evaluated, and interventions studied.
• study_type: a text category, in which is described the nature of the investiga-
tion and usage for which clinical study information is being submitted. This
attribute can be found by the following categories: interventional, observa-
tional and expanded access.
• intervention_type: a text category, describing the type of intervention stud-
ied in the clinical trial. The intervention types may be found as the following
categories:
– Drug including placebo.
– Device including sham.
– Biological-Vaccine.
– Procedure-Surgery.
– Radiation.
– Behavioral as psychotherapy and lifestyle counseling.
– Genetic including gene transfer, stem cell and recombinant DNA.
– Dietary Supplement as vitamins, minerals.
– Combination Product combining different intervention types.
– Diagnostic Test as imaging, in-vitro and others.
• minimum_age: a numerical value, which indicates the minimum age a poten-
tial participant must meet to be eligible for the clinical study.
• maximum_age: a numerical value, which indicates the maximum age a poten-
tial participant must meet to be eligible for the clinical study.
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• mesh_term: a text term belonging to the NLM’s Medical Subject Headings2
(MeSH), considered as a clinical term of a systematized medical nomenclature
within the Unified Medical Language System3 (UMLS) Metathesaurus.
• condition_browse: a text section, that contains a list of mesh terms.
• condition: a text term, which represents the name of the disease studied in the
clinical trial.
• phase: a text category, which represents the numerical phase of the clinical trial
related to the stages of a trial from the preliminary experiments to the analytic
review of the advantages and disadvantages of a trial already approved by
FDA. The following phases of the CT are:
– N/A: not phases considered for behavioral studies.
– Phase 0: a limited human exposure to clinical procedures.
– Phase 1: a metabolism analysis after patient’s drug reaction.
– Phase 2: an evaluation of effectiveness of a drug.
– Phase 3: a specific analysis of effectiveness after having preliminary evi-
dence of effectiveness.
– Phase 4: a study over FDA approved drugs to clarify risks, benefits and
optimal use.
• keyword: a text term, which represent words or phrases that best describe
the protocol. Keywords consider The NLM’s Medical Subject Heading (MeSH)
controlled vocabulary to keep a consistency in research writings. Additionally,
keywords writing consider avoiding acronyms and abbreviations.
Furthermore, after flagged the XML field (Eligibility Criteria) from CORPUS as rele-
vant to compose BOW, we proceed to perform the following NLP subtasks:
• Eligibility Criteria textual information extraction.
• Data Cleansing removing XML tags, filtering senseless symbols and term low-
ercasing.
• Text Tokenization (keeping terms with at least 2 characters) including Lemmati-
zation.
Remarking the relevance of the NLP subtasks, we can denote that the main reason of
using Lemmatization instead of Stemming is related with both techniques properties.
Stemming algorithms work by cutting off the beginning or end of the word, taking
into account a list of common prefixes and suffixes that can be found in an inflected
word. On the other hand, lemmatization takes into consideration the morphological
analysis of the words, requiring language dictionaries queries. So Stemming is less
precise, faster to compute but less error prone than Lemmatization.
Interestingly, lemma obtained by lemmatization, is the base form of all its inflectional
2https://www.ncbi.nlm.nih.gov/mesh
3https://www.nlm.nih.gov/research/umls/
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forms, whereas a stem is not. Therefore, the reduction of the inflected words to the
base form is performed more accurately by the morphological analysis of lemmati-
zation rather than stemming.
Additionally, lemmatization seem to be suitable for this type of application since
does not require keeping language verb tenses as other NLP application. Besides,
another advantage of lemmatizing terms relies at reducing considerably the number
of features in BOW, which have an important impact to data dimensions.
Given our BOW model for representing the document content, this limited linguis-
tic process is enough for our needs, without using more sophisticated tools, as POS
taggers, syntactic parsers, etc. After this step we are ready to collect all the stems for
building the BOW representation.
2.5 Text Vectorization in Clinical Trials
After generating BOW from CORPUS and having samples truth values from the
scoring extraction stage, we proceed to extract numeric features to compose the
learning dataset. According to [33], the most representative Text Vectorizers are:
• Count Vectorizer.
• Tfidf Vectorizer.
Based on [33], Count and Tfidf vectorizers4 represent a document as a numerical vec-
tor of n dimensions where each dimension corresponds to a word of the vocabulary
BOW (a lemma in our case). So, n used to be large and the vector very sparse (i.e.
having a big amount of zero values).
The difference between the two approaches is reduced to the way of weighting the
components of the vector. After, establishing comparisons among both approaches,
Tfidf weighting seem to represent term relevance in a better way than Count, which
represent a raw frequency of a term in a document. Therefore, Tfidf approach has
been considered represent CORPUS as set of vectors.
In short we are going to describe the Tfidf feature extraction approach [33], where
the first denote the un-normalized calculation and the second the L2 normalization of
the first one:
t f _id f (t, d) = t f (t, d) ∗ (1+ log 1+ nd
1+ d f (d, t)
)
t f _id f (t, d)_norm =
t f _id f (t, d)√
nt
∑
i=1
t f _id f (ti, d)2
where:
d : A given document.
4Frequently count and tfidf vectors are normalized for getting a true probabilistic distribution, i.e. to
transform the vectors into unitary vectors. Normalization simply consists on dividing each component
by the summation of all of them
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t : A given term in a d document.
nd : Number of documents in CORPUS.
nt : Number of terms in the document d.
ti : i-th term in document d.
t f (t, d) : Raw occurrences of term t in document d.
d f (d, t) : Number of documents where term t occurs.
Following this approach we obtained a sparse continuous matrix (i.e. with a higher
presence of zeros), Document Term Matrix (DTM).
FIGURE 2.4: CT CORPUS representation as Document Term Matrix.
As we can observe in Figure 2.4, DTM columns represent the terms (lemmas) of BOW
in alphabetic order, whether the rows resemble the documents in our CORPUS.
Furthermore, in Appendix B can be found an example of the 25 most discriminant
terms for every different configuration of ngram_ranges. This feature relevance evi-
dence; consider combinations from 1 to 3 words in a single BOW term.
Getting into details, Sklearn Vectorizers [33] have interesting NLP properties:
• ngram_range.
• min_d f .
• max_d f .
• max_ f eatures.
The first parameter ngram_range, has to do with features representation, in which
every BOW feature can contain one or more words in sequence (i.e. mono− grams, bi−
grams, tri− grams, .., n− grams).
The second and third parameters min_d f & max_d f , stand for regulation of the
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mathematical concept id f from the t f − id f equation previously mentioned. The
effect of adjusting these two parameters into lower-medium values consider only
terms that appear with lower frequency in the CORPUS.
Consequently, after calculating the logarithm of a value higher than one, lead to
influence proportionally positive the final t f − id f score of the term considered at
the calculation. Therefore, Text Vectorizer only keep the terms with a relevant id f
value to build features data matrix.
Hence, in this application we consider the usage of different configurations, which
are mentioned in Chapter 5: Experiments.
Finally, the last parameter max_ f eatures, help to keep only the max number of fea-
tures with the most higher t f − id f value. Default parametric value, retrieves all the
terms that can be possibly extracted. Interestingly, this parameter may be suitable in
cases where the number of samples is lower and therefore, number of features must
be constrained to a relatively lower value.
Besides, this parameters may be suitable, in cases when there is n > 1 at ngram_range
values since the number of possible features increase highly.
After obtained a data matrix from the Feature Extraction stage, we obtained a higher
dimension sparse matrix. The sparsity comprise the low or null relevance of specific
terms for a particular CT based on the t f − id f metric.
As it was previously commented, the number of lemmas in BOW represents DTM
dimension. Particularly in our application after performing all the NLP subtasks
previously mentioned, we constrained the maximum number of lemmas as 15,296,
for every ngramcombination, which is the maximum number of mono-gram features
found by the vectorizer.
As we can observe, the number of features exceed the number samples available,
for this reason we decided to perform Data Projections, i.e. Dimensionality Reduction
techniques. In short we are going to describe how data projections can be done per-
forming features mapping.
2.6 Data Projections (Features Mapping)
This feature selection approach aims to find a useful representation of the data, map-
ping features to a more representative numerical space. This approach does not
involve a manual removing of the features but a projection of them that most of
the time implies a linear and non-linear combination among them. These type of
methods help to reduce data dimensions, by finding the k significant features as a
projection of the originals d. The main advantages of dimensionality reduction are:
• Finding a mathematical representation within which you can describe most
but not all of the variance within your data, retaining relevant information but
reduced to a considerable size to ease model induction.
• Preserving its Euclidean structure but does not suffer from curse of dimen-
sionality (i.e. data become highly sparse making unfeasible learning for ML
algorithms that require statistical significance).
This analysis is usually performed by the general real matrix factorization method,
Single Value Decomposition (SVD) [36] [5]. SVD is considered a generic method that
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can obtain PCA after performing matrix factorization of a covariance matrix.
There are many implementations available of LSA, PCA and related approaches.
From these I have chosen SVD-Truncated, included within Sklearn for the following
reasons:
• SVD-Truncated robustness compared to PCA, since it can be applied to distance
and similarity matrices.
• SVD-Truncated robustness to deal with sparse data from a non-numerical na-
ture, (e.g. lemmas encoded as numerical values) in comparison with PCA.
• SVD-Truncated combines features (lemmas) values having close meaning by
means of weights resulting as robust to synonymy and polysemy by grouping
similar features.
• SVD-Truncated cheaper numerical calculations over sparse data, since it does
not standardize data before computing SVD, this result as an efficient perfor-
mance.
• SVD-Truncated framework is suitable for matrices formed with Count or Tfidf
vectors.
The SVD-Truncated sklearn configuration parameters are: n_components, algorithm,
n_iter, and random_state. The first parameter stands for the desired dimensionality
of the projection. The second parameter consider the algorithm under the projection
task, either ARPACK or Randomized. The last two parameters depend highly on the
algorithm implemented. Remarkably, we have to point out that the components and
the projection obtained are sensible to the algorithm and random state properties.
2.7 Clinical Trial Prediction Evaluation Metrics
After obtaining a representative dataset, we continue describing the error metrics
considered by the Machine Learning (ML) models implemented in this task. For the
sake of proper clarifications of the solving approach, as it was previously mentioned,
we considered to accomplish the multi-output, multi-label classification task as mul-
tivariate regression task taking as an advantage a potential representation a numeri-
cal range of classes as two numerical values representing the min and max values of
a range of numbers comprising ECOG or KPS scales.
For this reason, we considered regression predictions metrics in this task. According
to literature the most well known regression error measures are: Mean Squared Error
(MSE) and Scaled MSE (1− R2). Remarkably, 1− R2 metric intends to explain how
big is the prediction error in proportion with the variance of the truths. Based on
[32], this metric is commonly used as model performance indicator, in which lower
values mean higher performance.
Consequently, we are going to consider MSE and 1− R2 metrics to asses error and
proportion of response variance captured by the model.
To notice, the usage of this metrics consider a multivariate regression task, in which
we intend to predict two values min and max scores from breast cancer CT patient’s
profile range.
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MSE(X, yj) =
n
∑
i=1
( f (xi)− yi,j)2
n
where:
X : all features from all the samples in data.
yj : j-th component from all the samples responses values (integer vec-
tor).
n : number of samples in data.
xi : all features from i-th sample (continuous vector).
yi,j : j-th response value component of i-th sample (integer value).
Range : range values depend on the y-domain values. Being 0 an ideal
value.
VAR(yj) =
n
∑
i=1
(yi,j − y¯j)2
n
where:
yj : j-th component from all the samples responses values (integer vec-
tor).
n : number of samples in data.
y¯j : Mean value of the j-th component from all the samples responses
values (continuous value).
yi,j : j-th response value component of i-th sample (integer value).
1− R2(X, yj) =
MSE(X, yj)
VAR(yj)
1− R2(X, yj) ∈ [0, 1)
where:
X : all features from all the samples in data.
yj : j-th component from all the samples responses values (integer vec-
tor).
Range : range values normally oscillate between 0 and 1, however when
the MSE is higher than VAR(y), values may be higher than 1. The
lower the value the higher performance of the model.
2.8 Clinical Trial Multivariate Regression Complexity
In this section, we describe briefly the mathematic complexity behind CT multivari-
ate prediction problem in term of matrices operations. Interestingly, understanding
about task complexity always give descriptive insight of how costly is to perform
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a ML task in terms of computational resources. This analysis, is often required to
asses how difficult can be scaling the problem to big data scenarios.
For this analysis we are going to consider the following elements:
• Features matrix X: features data matrix extracted after performing Text Vec-
torization. Matrix dimensions are (n, m), in which n represent the number of
samples and m the number of features of BOW retrieved from Text Vectoriza-
tion.
• Response matrix Y: response data matrix. Matrix dimensions are (n, 2), in
which n represent the number of samples as X, and 2 the output variables min
and max ECOG/KPS scores respectively.
For the sake of description, the experiments described in this research n is set to
4, 023 and m to 15, 296. These values represent the samples with explicit ECOG/KPS
scoring, and the maximum number of unique single lemma terms in CORPUS.
For this analysis, we would consider a asymptotical complexity [25] [19] based on
the regression normal equation and assuming that the number of samples is bigger
than the number of features (e.g. n > m).
Task Operations Time Complexity
SVD Overall O(min(mn2, m2n))
Regression XtX O(m2n)
(XtX)−1 O(m3)
XtY O(m2n)
(XtX)−1XtY O(mn)
Overall O(m2n)
MSE X((XtX)−1XtY) O(m2n)
Y− (X((XtX)−1XtY)) 2n ∗Θ(log(d))
Overall O(m2n)
TABLE 2.4: CT multivariate regression task time complexity.
2.9 Learning Algorithms
In this section, we describe the algorithms implemented in the multivariate regres-
sion task considered in this work. For this application we found interesting the fact
of comparing ML predictors with a different complexity to represent the tendency
of data (i.e. linear or non-linear) way to fit data. Considering the type of prediction
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task and data properties as high-dimensional spaces after extracting features at Text
Vectorization, we considered that the most appropriate candidates for the task given
the previously mentioned conditions are: Partial Least Square (PLS) as a linear model
and Multi-Layer Perceptron (MLP) neural network as a non-linear model.
2.9.1 Partial Least Square (PLS)
Proposed by the Swedish Statistician, Herman O. A. Wold in 1975 [17]. The algo-
rithm is featured by the following specifications:
• A bi-linear factor model.
• A latent variable approach related to PCA.
• Finds a linear regression over X and Y projections into a new space.
• Suitable when there are more features than samples in the dataset.
• Suitable when there exist multi-collinearity among predictor variables X.
• Applied frequently at chemo metrics, bioinformatics, anthropology and neu-
roscience analyses.
The PLS algorithm is represented by the mathematical expressions, in which X and
Y represent features and response matrices from a given dataset:
X = TPT + E
where:
n : Number of samples in data.
m : Number of features in data (after dimensionality reduction).
X : Features data, (n, m) data matrix.
T : Numerical mapping of X, (n, l) data matrix.
P : Weights coefficients (m, l) matrix.
E : Error (n, m) matrix, assuming independently random distribution.
Y = UQT + F
where:
n : Number of samples in data.
p : Number of response variables in data.
Y : Response data, (n, p) data matrix.
U : Numerical mapping of Y, (n, l) data matrix.
Q : Weights coefficients (p, l) matrix.
F : Error (n, p) matrix, assuming independently random distribution.
X and Y decompositions aim to maximize the covariance between T and U in such a
way that projected variables of X are correlated with projected variables of Y, show-
ing consistency among features and responses on the new projected space.
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2.9.2 Multilayer Perceptron (MLP)
As an alternative to the bi-linear model PLS we decided to try a non-linear model
from the family of Neural Network (NN) model. Being the size of our dataset for
learning rather small, it is out of consideration to use a deep learning model, that
need a big dataset for learning. We decided, so, to move to a simple Feed Forward
approach, specifically a Multilayer Perceptron (MLP). MLP has its foundations on
former research related to Single Layer Perceptron by McCulloch and Pitts in 1940,
the first model symbolized a neuron that worked as a linear model combining in-
puts with respective weights. This model was applied either as binary classification
problems that required threshold and step functions or as a regression task that ap-
plied a simple linear combination considering bias. Based on the fact that a unique
neuron was not capable to discriminate among non-separable data, and after some
studies in 4 decades, in 1985 McClelland and Rumelhart proposed neuron based im-
proved model that was capable to track non-linear problems, Multilayer Perceptron
[34]. The MLP algorithm is featured by the following specifications:
• A non-linear model.
• An abstraction of cognitive and neural learning and connectionism among
neurons.
• An architecture where all the neurons of the network are fully connected.
• A feed-forward approach, where learning starts from the first hidden layer
and goes through the other hidden layers to the output layer, with no cycles or
loops.
• Neurons have non-linear activation functions, (i.e. inputs come through a non-
linear function).
• Several neuron activation functions could be used: tanh, sigmoid (logistic), relu
(semi-linear) as shown in Table 2.5.
• Network weights are learned by back propagation approach, which refines
weights by a gradient descent error respect to networks weights modulated by
a learning rate. The most popular learning algorithm for this kind of network
is the Stochastic Gradient Descent, .
• A typical network architecture comprises inputs, a hidden layer and an output
layer. This fact is based on The Universal Approximation Theorem, in which a
continuous function that maps intervals of real numbers can be approximated
arbitrarily closely by Multilayer Perceptron with just one hidden layer.
The algorithm considers the following expressions related to delta rule considering
the X(n,m), Y(n,p) dataset features and responses respectively and z neuron input:
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Name Mathematical Expression
Identity f (z) = z
Rectified Linear Unit (Relu) R(z) = max(0, z)
Sigmoid (Logistic) σ(z) = 11+e−z
Hyperbolic Tangential tanh(z) = 21+e−2z − 1
TABLE 2.5: MLP Activation functions.
MLP Delta Rule for Iterative Learning MLP algorithm comprises an optimization
algorithm that seeks to minimize error, adjusting weights values to approximate re-
sponse variables. The optimization method implemented is gradient descent, which
calculates the weights with minimum error by obtaining the partial derivate of the
weight errors respect to the weights.
E(w) =
1
2
n
∑
i=1
(Yi,k − f (Xi))2 =
n
∑
i=1
[Yi,k − g(
d
∑
j=1
wjXi,j + w0)]2|∀k ∈ p
where:
E(w) : weights error function.
i : index of i-th sample.
n : Number of samples.
j : index of j-th neuron.
d : Number of neurons.
k : index of k-th response variable.
p : Number of response variables.
Yi,k : k-th response value of i-th sample.
f (Xi) : Hypothesis value of the i-th sample.
g(X, w) : g activation function.
wj : j-th neuron weight.
Xi,j) : j-th feature of the i-th sample.
w0 : Threshold/bias.
In order to obtain minimum error derivative has to be calculated obtaining the fol-
lowing expression:
∂E(w)
∂wj
= −
n
∑
i=1
(Yi,k − f (Xi))g′(wTXi)Xi,j|∀k ∈ p
where:
∂E(w)
∂wj
: partial derivate of weight errors respect to the j-th neuron weight.
i : index of i-th sample.
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n : Number of samples.
j : index of j-th neuron.
k : index of k-th response variable.
p : Number of response variables.
Yi,k : k-th response value of i-th sample.
f (Xi) : Hypothesis value of the i-th sample.
g′(X, w) : Derivate g activation function.
wj : j-th neuron weight.
Xi,j) : j-th feature of the i-th sample.
Consequently if g activation function is the identity from Table 2.5 we obtained the
Least Means Squares (LMS) function:
∆wj(Yk) = α
n
∑
i=1
(Yi,k − f (Xi))Xi,j|∀k ∈ p
where:
∆wj(Yk) : increment of j-th weight considering k-th response variable.
α : learning rate.
i : index of i-th sample.
n : Number of samples.
k : index of k-th response variable.
p : Number of response variables.
Yi,k : k-th response value of i-th sample.
Xi,j : j-th feature vale of the i-th sample.
f (Xi) : Hypothesis value of the i-th sample.
These techniques represent a linear Regressor where weights are estimated itera-
tively the most applied learning rule according to the literature. After this formu-
lation, the same expression can be adapted for iterative algorithmic considering t
number of iterations, with a variable learning rate as the following expression:
∆wj(t) = αt(Yi(t) − f (Xi(t)))Xi(t),j
where:
t : index of t-th iteration.
∆wj(t) : increment of j-th weight at t-th iteration.
αt : learning rate at t-th iteration.
Yi(t) : i-th sample response value at t-th iteration.
Xi(t),j : j-th feature vale of the i-th sample at t-th iteration.
f (Xi(t)) : hypothesis value of the i-th sample at t-th iteration.
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2.10 Pros & Cons of Solving Methodology
As every formal scientific research, a balance between the advantages and disad-
vantages of the methodology proposed in this thesis is required in order to observe
the strengths and particularities of the contribution presented in this work as the
vulnerabilities or potential improvements in term of performance and accuracy at
predictions of the Clinical Trials (CT) profiles considering ECOG/KPS scales.
Advantages of NLP & ML Methodology
• NLP robust framework to perform extraction of the response values of dataset
represented as ranges bounds min & max. Note that, when present, this infor-
mation occurs in a variety of formats.
• NLP robust framework to perform text cleaning and pre-processing Stop word-
Removal, Stemming, Tokenization in order to preparing the text for further fea-
ture extraction.
• NLP robust framework to perform Text Vectorization to explore different repre-
sentations of features as n_grams combinations, keeping the most representa-
tive features based on t f − id f .
• ML sparse robust Single Value Decomposition method to project features ex-
tracted by Text Vectorization to a more feasible separable space.
• ML suitable PLS bi-linear factor model to predict multivariate ECOG/KPS
scores, in high dimensional data, in which the number of samples is lower
than the number of features.
• ML suitable MLP non-linear model to predict multivariate ECOG/KPS scores,
in high dimensional data, feasible to generate data distribution of non-separable
data.
Disadvantages of current NLP & ML Methodology The proposed approach presents,
however, some limitations that could be addressed as future work.
• NLP potential improvement considering specific medical NLP annotation tools
as Metamap[7], NCBO annotator[3], CTakes[35], Snow Med[37], etc. instead of the
general ones we have used. These tools may be useful to extract meaningful
features as medical entities, drugs, and treatments that could represent data
predictors in a more accurate way.
• NLP potential improvement considering Embedding of medical text. Embed-
ding, comprise mapping the sparse input vectors into dense, low dimensional
space. This adecuations can be performed at word level as Word2Vec[1], Glove[29],
for general language. Furthermore, Pyysalo[4] is suitable for the medical do-
main and complex language contexts. In fact embedding combines vectorizing
and dimensional reduction into one single step.
• ML potential fail in PLS assumption, in which PLS is profitable when there
is multi-collinearity in X predictor variables (i.e. some of the features have a
higher correlation among them).
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• ML potential fail in MLP consideration, in which a lower number of samples
compared to the number of features leads model to over fit training data fail-
ing to capture the statistical generation of the data. This may be solved by
implementing early stopping, drop out, or other criteria on MLP.
• ML potential fail in MLP back propagation property in terms of the speed of
convergence, the optimization algorithm may fall into local minima if speed of
convergence is higher. This may be solved using a low or adaptable learning
rate in MLP.
• NLP & ML potential improvement considering connection frameworks with
Hadoop, Map reduce, a MPI-Python to parallelize the task if the problem is scaled
to big data, though it is not the case in the problem at hand.
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State of the Art
Now a day, medical informatics has gained a higher importance through real life
applications. All these applications are categorized by different functionalities in
medicine such as: clinical decision support systems, medical and pharmaceutical
time line software analysis, underlying patterns in medical entities relation’s ana-
lytics, and many others. All these medical applications by computational resources
have brought more resources to extend life expectancy, safeness and comfort on hu-
man beings.
However, these real life applications face their own challenges and difficulties as:
• Localizing, classifying and removing ambiguities on medical NE from a high
variety of genres, some of them specially challenging as Electronic Health Records
(EHR) and Clinical Trials (CT).
• Extracting medical text related to measures, doses, units from these docu-
ments.
• Finding discriminant and compact representations of medical data.
• Tuning Machine Learning algorithms to such materials.
• Ensuring classification/prediction higher accuracy to give proper and accurate
results.
• Solving computational performance issues.
Therefore, relevant and profitable medical application has a lot of multi disciplinary
work behind them and consequently require dedicated work and research always
with an innovative and modern vision of life needs.
According to the most recent surveys from medical informatics, the cutting-edge
applications are: Clinical Decision Support (CDS) [13], Medical Question Answering
(MQA) [16], Finding Patterns in Annotation graphs [6], Semantic tagging of medical cate-
gories [12], Terminology Extraction for the Medical Domain [38], Metrics in Ontologies in
the Medical Domain [27], and In silico analysis of drugs [20].
Furthermore, related to the medical resources, the most prestigious and trustable
freely available data banks of clinical trials are ClinicalTrials.gov [11] and Linked CT
[21]. First of them store trials from all around the world and the second source is
composed by trials of different sources including the former ClinicalTrials.gov and is
built in generic and basic organization and visualization tools. Moreover, related to
ontologies, there are relevant and well know references available from BioPortal [18].
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Many BioMedical corpora are, too, publicly available [40]. Finally, another meaning-
ful resources related to the medical informatics are biomedical processors as NCBO
annotator [3] , Metamap [7], and CTakes [35] that ease the medical NE recognition task
resulting as a potential alternative for categorical features generation.
Furthermore, limiting medical informatics research to clinical trials applications there
are applications strongly related to the problem considered in this thesis.
One of these applications consider Karnofsky Performance Status (KPS) deploying an
algorithmic system for its evaluation. In [30], KPS is considered important as Clinical
Trial (CT) assessment criteria.
In this contribution there is an overview scale basis as a matter of discussion of its
subjectivity in the 1940’s, where cancer physicians and mental health professionals
found a higher correlation between cancer evolution and psychosocial aspects in
patients. Consequently after some researching, health professionals found 7 psy-
chosocial factors that empirically explain cancer evolution applying a multivariate
regression analysis. Notably, these factors now comprise part of the KPS scale-stage
descriptions. Moreover, this research established comparisons among other scales
such as ECOG and AKPS to KPS highlighting KPS advantages and no improve-
ments by the others. In their solving methodology, they proposed a Decision Tree
approach as a CT-KPS classification model.
FIGURE 3.1: Decision Tree CT-KPS Classification Model from [30].
According to the authors the system had a good performance for this type of appli-
cation, but they remark potential drawbacks and limitations faced by their CT-KPS
model. In short we are going to describe briefly the limitations of the model as part
of possible future improvements for similar applications:
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• The model assumes fixed and term-constrained inputs queries (textual/oral)
classification but has a lack of robustness against synonymy, polysemy and
other language ambiguities.
• The model is not robust against fuzzy input queries, e.g. “normal, no com-
plaints, no evidence of disease”, where the third term (i.e. no evidence of
disease) inputs fuzziness in the query, since patient may had previous cancer
experiences or family incidence, and as consequence system do not consider
potential fuzzy queries and outcomes.
• The model does not consider drug’s name entities or drug’s categories as data
features in the classification model.
• The model is not robust at predicting KPS range of stages, therefore is con-
strained to one stage KPS classification, and consequently it has a non-realistic
behavior according to CT KPS real profiles.
• The model is not induced by data inference, therefore they are not considering
the most updated features from ClinicalTrials.gov CT XMLs.
• There is not a defined evaluation for this classification model.
Moreover, another relevant clinical trial application is focused on performing data
mining over cancer vaccine trials. In this research [10], the authors try to enhance
the motivation of why collaborating with cancer through particular statistics from
The World Health Organization’s Global Burden of Disease (WHOGBD).
This work considers the gathering of relevant resources as bio-molecular ontologies
from The National Center for Bio-technology Information (NCBI) and as cancer vaccines
CT data from The US National Cancer Institute (NCI) through ClinicalTrialas.gov.
The work proposed a visualization framework that aims to understand the cancer
vaccines CT medical sector by extracting, summarizing, and generating demograph-
ics, statistics and plots from specific fields in the CT XML files. The final usage of
this work highlights relevant aspects as cancer vaccines timeline usage, survival per-
centages for different cancer types, and a distribution overview of treatments among
institutions all these bring as consequence a clear clinical and pharmaceutical advan-
tage in the market coverage.
Other applications of trials consider the implementation of medical annotators. An
example of this application utility[8] is the use of NCI Thesaurus to annotate CT and
graph representation of entities relations for data mining processes.
The annotations comprise clinical entities tags among CT conditions, drugs, etc. Ac-
cording to the authors, relevant relationships and patterns can be extracted from
annotated CT. The proposed framework considers the following stages:
1. Gathering data from an open link source LinkedCT.org [21] ClinicalTrial.gov [11]
XML CT data bank.
2. Implementation of ontologies as NCI Thesaurus & NCI Methasaurus to tag con-
ditions, drugs, etc. with medical entities.
30 Chapter 3. State of the Art
3. Feeding a fully connected graph with all the medical entities tagged in all the
CT.
4. Performing Dense Sub Graph (DSG) generation to remove less relevant rela-
tions in terms of a taxonomic distance metric, in order to keep a compact but
informative representation of the graph.
5. Performing Graph Summarization (GS), representing graph as partitions of super-
nodes and super-edges, after edges addition-removal that encode more effi-
ciently the underlying relations of medical entities.
Another relevant application in CT is the automated extraction of clinical trial char-
acteristics from medical scope text [23]. Considering CT as the most important
sources of evidence for guiding evidence-based practice and the design of new tri-
als, most of this information is available only in free text (e.g. in journal publica-
tions). This denotes the intensive labor to process text for systematic reviews, meta-
analyses, and other evidence synthesis studies.
[23] propose a framework that assists users with locating and extracting key trial
characteristics (e.g. eligibility criteria, sample size, drug dosage, primary outcomes)
from full-text journal articles reporting on randomized controlled trials (RCT).
The framework proposed consider the following modules:
• An information extraction (IE) engine that searches the article for text frag-
ments that best describe the trial characteristics.
• A web browser-based user interface that allows human reviewers to assess and
modify the suggested selections.
The IE engine implements a statistical text classifier to locate those sentences that
have the highest probability of describing a trial characteristic. After that, the second
module applies simple rules to these sentences to extract text fragments containing
the target answer. As a research extension, in The Human Studies Database (HSDB)
Project, there are federating the computable description of trial design, execution,
and results to support large-scale data analysis and synthesis across many ongoing
and completed studies.
Additionally, according to [2] eligibility criteria extraction problem has been rec-
ognized as a relevant functionality for CT data mining. This work considers the fact
that eligibility criteria fields in clinical trials are represented as free text, therefore,
their automatic interpretation and the evaluation of patient eligibility is challenging.
The approach proposed in this work considers the identification of contextual pat-
terns and semantic concepts that together define the machine-interpretable meaning.
Consequently, their aim is to find the most relevant concepts occurring in eligibility
criteria that need to be mapped to patient record to enable automatic evaluation
of patient eligibility. The research considers exploring the concepts that occur in
eligibility criteria related to a particular disease. And as a consequence identified
concepts will be used to link to corresponding data items in patient record, to enable
evaluation of patient eligibility.
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Finally, there is another recent application [15] related to CT focused on evaluation
of the use of document similarity methods to retrieve unreported links between Clin-
icalTrials.gov [11] and PubMed [24]. In this work, they considered extraction of terms
and concepts of 72, 469 structured XML files from ClinicalTrials.gov and 276, 307 reg-
istry entries from PubMed. Besides, they implemented tested methods for ranking
articles across 16, 005 reported links and 90 manually-identified unreported links.
The research considered the usage of distance metrics as Euclidean distance, Cosine,
and Jaccard. Moreover, performance was assessed by the median rank of matching
articles, and the proportion of unreported links that could be found by screening
ranked candidate articles in order.
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Experiments
In the following section we describe the experiments done in this work. These ex-
periments comprise different tuning configurations from multiple parameters of the
different steps of prediction task namely:
• Text Vectorization.
• Data Projection.
• Prediction Refining.
• Sample Problematic Cases Removing
• Model Tuning.
As stated in Chapter 2, we will compare two different regressors, a bi-linear PLS
and a non linear MLP in order to find the most appropriate type of model for the
particular medical considered in this work.
Furthermore, we found these two particular models suitable considering their prop-
erty of predicting multi-output values. Considering the previously mentioned wrap
around from classification to prediction in task we must consider both models PLSRegressor
and MLPRegressor to solve the regression task.
However, we started the experimental results analysis considering default param-
eters in both algorithms that will be subject to tuning in further stages of the exper-
imentation. Therefore, let us describe now the default parameters of both models
based Python Sklearn framework.
1. PLSRegression parameters:
• n_components = 2
• copy = True,
• max_iter = 500
• scale = True
• tol = 1e− 02
2. MLPRegressor parameters:
• solver =′ lb f gs′
• alpha = 1e− 05
• activation =′ relu′
• hidden_layer_sizes = (10, 1)
• tol = 0.0001
• max_iter = 200
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• random_state = 99
• early_stopping = False
• warm_start = False
4.1 Dataset specifications
After a brief descriptions of the algorithms implemented in this work and a previous
description of data in Chapter 2, we will reference data source to clinicaltrials.gov.The
biggest and most popular source of trials freely available. Remarking that dataset
was updated by the last CT available March 2018.
Country Cancer Breast
Cancer
U.S. only 31,268 4,316
Non-U.S. only 29,544 3,791
Total 60,812 8,107
TABLE 4.1: Distribution of CT researching on cancer/breast cancer
performed by the U.S. and Non-U.S. countries.
Additionally, we must mentioned that the testing/training slicing framework was
based on 10-Fold-CV, in which we train and predict 10 times using 90% and 10% for
training and testing respectively.
Furthermore, let us describe the particularities of the data used to train models for a
KPS and ECOG PS prediction types. Hence, as it was previously mentioned in Chap-
ter 2 the samples we only considered for training set (4023) have the ECOG/KPS
explicit score ranges in eligibility criteria.
Performance Status Samples Features
KPS 3,767 15,296
ECOG 4,023 15,296
TABLE 4.2: Dataset sizes considered for KPS and ECOG predictions.
As we may observe the samples used on each PS scale prediction vary, consider-
ing that KPS predictions generalize better without problematic samples, which are
not statistically relevant. Although, ECOG predictions are induced more accurately
on the complete set of samples. The justification of this can be proved in further
experimentation sections of the current chapter.
4.2 Experimentation in Text Vectorization
To begin with, the main reason of performing text vectorization is that raw data
(clinical text), a sequence of symbols cannot be input directly into the algorithms
themselves since most of them expect numerical feature vectors with a fixed size
rather than the raw text documents, which have a variable length.
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Therefore, we applied vectorization, which is a general process of turning a col-
lection of text documents into numerical feature vectors. This specific strategy con-
sidered, BOW, comprises different pre-processing tasks, as stop words removal, to-
kenization, counting and normalization.
Documents are described by word occurrences/relevance while completely ignor-
ing the relative position of the words in the document. Furthermore, as word rel-
evance analyzer we considered a Tfidf-Vectorizer by resulting the most descriptive
indicator.
This indicator can be seen as alocal-global analysis of each term (lemma).The local
indicator can be referred as the first Tfidf component Term Frequency, which gives an
insight of how relevant is the word by its frequency in a particular document.
Besides, global indicator Tfidf second component, gives the insight of how discrimi-
nant the lemma by the number of documents that contain the term.
1. TfidfVectorizer parameters:
• stop_words
• max_d f
• min_d f
• max_ f eatures
• ngram_range
• To start experimentations, we considered an English stop_words removal, since
these terms do not provide any discriminant information by having a higher
frequency among the text.
• In addition, based on Python Sklearn technical configurations on Tfidf Vectorizer,
we describe the min_d f and max_d f components.
max_d f parameter controls the words considered by text vectorization by lim-
iting words that appear in a certain number of documents. The Python Sklearn
framework allow to give integer values (i.e. number of documents) or real val-
ues (i.e. the fraction of documents) as constrain, therefore if max_d f is set on
0.50 it will only considered lemmas that appear in 50% of CORPUS documents
approximately.
Consequently, after some experimentations with the different real values con-
figurations: [0.0, 1.0] in intervals of 0.25, we found that the best value for the
attribute max_d f is 0.25, based on the framework functionality, min_d f is con-
sidered by default as 0.0.
• Furthermore, for max_ f eatures parameter we did not set any special value
along with ngram_range = (1, 1) to observe how many different and relevant
terms according to the previous vectorizer parameters recently sat. We found
15, 296 as the maximum intrinsic number of features. Additionally, considered
the different percentages [0.125, 0.25, 0.50, 0.75, 1.0]% as different max_ f eatures
(number of features constraint) configurations.
• Finally, ngram_range as the last parameter to tune in Text Vectorization, we
tried different configurations considering: mono-grams, bi-grams and tri-grams.
This assumptions are based on medical text work done from literature [39], in
which they suggest the importance of considering the n-gram up to 3. More-
over, vectorizer can handle two types of ngram_ranges, fixed BOW n_gram
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length (e.g. (1, 1) where BOW has n_grams within same number of words) or
variable length (e.g. (1, 3) where BOW has n_grams within variable number of
words, one, two or three words in a token). We considered the following dif-
ferent ngram_ranges pairs of values [(1, 1), (1, 2), (1, 3), (2, 2), (2, 3), (3, 3)].The
ngram_ranges tuple components represent the minimum and the maximum
number of words considered for a given text vectorization.
The following TextVectorization experimental results aim to find a leading path of
which are the most suitable representations of the data.
This fact considers different configurations max_ f eatures and ngram_ranges in or-
der to find which configurations minimize MSE and 1− R2.
As we previously mentioned in Chapter 2, MSE is the traditional metric to asses
prediction errors, and 1− R2 describes how great is the Y¯ error with relation to the
var(Y),(i.e. if the variance of the truth is higher than the prediction error, the model
may be induced from the data in a proper way).
We initially considered a KPS prediction without any translation to ECOG scale,
a decimal rounding, a 5-10 multiple rounding (considering KPS 10-stage intervals)
and a post-prediction maximum values constrain over the Full − Set of samples
(4023) CT.
All this considerations were taken into account at implementing PLS and MLP mod-
els to this task. Hence we calculated the variance per every KPS score from the
truths, var(ymin) = 298.939 and var(ymax) = 238.065 for posterior comparison pur-
poses.
After computing all the different combination of Text Vectorization configurations we
found the following learning behaviors in PLS and MLP simulations respectively:
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FIGURE 4.1: 10-CV Testing KPSmin : 1−R2 & MSE scores obtained by
different ngram_range & max_ f eatures configurations implementing
PLS.
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As we can observe in the preliminary simulations in PLS to predict KPSmin,
the most suitable ngram_combinations are located in middle representa-
tions of lemmas as features as (1,2) and (2,2) (i.e. features that represent
one or two lemmas, and features that represent two lemmas). For this
configurations, MSE and 1− R2 minimizations show a consistent behav-
ior, leading to the minimum values. Furthermore, the worst features rep-
resentations are (2,3) and (3,3) representing complex features with two or
more lemmas contained.
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FIGURE 4.2: 10-CV Testing KPSmax : 1− R2 & MSE scores obtained
by different ngram_range & max_ f eatures configurations implement-
ing PLS.
As we can observe in the preliminary simulations in PLS to predict KPSmax are con-
gruent with simulation behaviors of KPSmin. The most suitable ngram_combinations
are located in middle representations of lemmas as features as (1,2) and (2,2) (i.e.
features that represent one or two lemmas, and features that represent two lemmas).
For this configurations, MSE and 1− R2 minimizations show a consistent behavior,
leading to the minimum values. Remarkably, the worst features representations are
(1,3) and (3,3) representing configurations from extreme bounds considered. This
may suggest that in general features containing three lemmas may be complex and
do not provide discriminant information.
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FIGURE 4.3: 10-CV Testing KPSmin : 1−R2 & MSE scores obtained by
different ngram_range & max_ f eatures configurations implementing
MLP.
As we can observe in the preliminary simulations in MLP to predict
KPSmin, neural network default parameters over fit when the number
of features decrease from the maximum. Based only on the results con-
sidering the maximum number of features we can observe that the most
suitable ngram_combinations are located in complex features representa-
tions, in which there are more than one lemma contained. For this config-
urations, MSE and 1− R2 leading to the minimum values in proportion
to the number of lemmas considered in the text vectorization. Remark-
ably, the worst features representations are (1,1) representing low com-
plexity features compositions. This may suggest that MLP learning may
generalize better among complex features representations in text vector-
ization.
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FIGURE 4.4: 10-CV Testing KPSmax : 1− R2 & MSE scores obtained
by different ngram_range & max_ f eatures configurations implement-
ing MLP.
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As we can observe in the preliminary simulations in MLP to predict KPSmax, re-
sults seem to be congruent with KPSmax predictions. As we can see, neural network
default parameters over fit when the number of features decrease from the maxi-
mum. Based only on the results considering the maximum number of features we
can observe that the most suitable ngram_combinations are located in complex fea-
tures representations, in which there are more than one lemma contained in features
except from (1,3) configurations. For (1,2), (2,2), (2,3) and (3,3) configurations, MSE
and 1− R2 lead to the minimum values. Remarkably, the worst features represen-
tations are (1,1) and (1,3) representing low complexity features compositions. This
may confirm that MLP learning may generalize better among complex features rep-
resentations in text vectorization.
After analyzing the behavior of the algorithms, we can infer that MLP with a de-
fault configuration has a strong tendency to over fit the data after feature removing
compared to PLS model.
Furthermore, the following tables that summarize plots results denote the most
profitable data representations per every ngram_range configurations according to
1− R2 & MSE scores minimization. This results display the type of Text Vectorization
that seem to be more suitable to train a prediction model.
Ngram Features 1− R2min 1− R2max MSEmin MSEmax
1, 1 15 296 1.029 1.098 307.698 261.595
1, 2 1912 1.046 1.055 312.942 251.252
1, 3 1912 1.037 1.062 310.053 253.040
2, 2 15 296 1.045 1.077 312.574 256.618
2, 3 1912 1.089 1.114 325.693 265.326
3, 3 15 296 1.103 1.107 329.836 263.544
TABLE 4.3: Best 10-CV testing MSE & 1− R2 configurations obtained
for PLS.
Ngram Features 1− R2min 1− R2max MSEmin MSEmax
1, 1 11 472 1.001 1.158 299.335 275.702
1, 2 11 472 1.001 1.158 299.335 275.702
1, 3 11 472 1.001 1.158 299.335 275.702
2, 2 15 296 1.050 1.092 313.916 260.040
2, 3 11 472 1.001 1.158 299.335 275.702
3, 3 11 472 1.001 1.158 299.335 275.702
TABLE 4.4: Best 10-CV testing MSE & 1− R2 configurations obtained
for MLP.
We can observe from the results of the BreastCancer CT Text Vectorization that PLS
with default configuration tends to generalize more precisely over simple ngramrange
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configurations (i.e. in which BOW terms contain tokens with one lemma) than com-
plex features representations. Besides, linear models seem to fit better in extreme-
size cases, in which data has big or small sizes.
Furthermore, as PLS, MLP seem to generalize better under non-complex features
representations in Text Vectorization.
Interestingly, MLP with default parameters seems to over fit quickly and get stuck
in local minima at weight adjustment. Therefore, the non-linear algorithm does not
improve metrics when the number of features decrease from the maximum value as
it can be seen in Figures 4.3 & 4.4.
After the Text Vectorization analysis, we considered other forms to boost predictive
models learning, one of them relies in Dimensionality Reduction or Feature Selection.
Dimensionality reduction considers reducing number of features to avoid The Curse
of Dimensionality Problem, in which the data dimensionality, space and sparseness
increase proportionally. Consequently, sparsity and higher dimensions represent a
learning issue by statistical models at developing a high-variance model, especially
in cases, intending to fit higher dissimilarities between samples.
In order to avoid The Curse of Dimensionality Problem, we are going to consider Di-
mensionality Reduction by applying a data projections in low-dimensional spaces. In
which the available max features considered are going to be combined and repre-
sented in a more discriminant form.
4.3 Experimenting in Data Projections
At Data Projection experiments we are going to consider the Single Value Decompo-
sition (SVD) previously mentioned in Chapter 2 by the advantages previously de-
scribed and its general matrix decomposition framework suitable for sparse data.
Ideally, we considered dimensionality reduction intending to keep the most rep-
resentative data attributes in a lower dimension considering the number of sam-
ples. This fact will result in robustness to The Curse of Dimensionality Problem. In
the following simulations we considered the full set of samples taking into account
var(ymin) = 298.939 and var(ymax) = 238.065, respective variances of KPSmin &
KPSmax scores.
Ngram Features 1− R2min 1− R2max MSEmin MSEmax
1, 1 32 0.996 1.051 297.888 250.373
1, 2 252 0.964 1.025 288.252 244.253
1, 3 252 0.950 1.022 284.128 243.382
2, 2 252 0.980 1.015 293.197 241.816
2, 3 252 0.987 1.017 295.217 242.167
3, 3 503 0.995 1.017 297.741 242.338
TABLE 4.5: Best 10-CV testing MSE & 1− R2 configurations obtained
for PLS for different SVD dimensions.
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Ngram Features 1− R2min 1− R2max MSEmin MSEmax
1, 1 63 1.018 1.109 304.328 264.063
1, 2 63 0.994 1.069 297.294 254.617
1, 3 63 0.998 1.080 298.512 257.321
2, 2 63 1.008 1.081 301.598 257.544
2, 3 252 1.001 1.158 299.335 275.702
3, 3 252 1.001 1.158 299.335 275.702
TABLE 4.6: Best 10-CV testing MSE & 1− R2 configurations obtained
for MLP for different SVD dimensions.
After results obtained in Table 4.5 and Table 4.6, we observe that after applying SVD
projections over Text Vectorization data, PLS models seem to be consequent in gen-
eralization metrics over simple ngramrange configurations. This fact denotes that
PLS best generalization results, comprise BOW’s terms contain tokens with single
lemmas. Moreover, linear models seem to generalize in a better in SVD projections
than only Text Vectorization data. Furthermore, for PLS, SVD projections of approxi-
mately 250 projected features seem to be representative for generalization purposes.
Additionally, MLP model seem to be consequent to Text Vectorization generalization.
Furthermore, after data mapping, non-linear models seem to generalize better on
reasonably lower SVD dimensions as 63 approximations in number of features.
4.4 Experimenting in Prediction Refining
After a brief review analysis of data representation from Text Vectorization and Data
Projection in PLS and MLP default tuning, we found that both of the models show a
better learning performance among data representations that contain mono-lemma
terms in BOW.
This fact can be observed particularly at following ngram_ranges: 1, 1, 1, 2, and 1, 3.
Furthermore, SVD data projections seem to re-fine the learning for each data repre-
sentation, since it can be seen that best data projections are found approximately in
the same ngram_ranges as the Text Vectorization data representations.
Interestingly, aiming to improve generalization in Breast Cancer CT profile predic-
tions, we decide to devote some experimentations related to refining final predic-
tions. We consequently considered that prediction refining may lead to a better
scores in testing results.
Therefore, for prediction refining we considered 3 aspects as potential tunings: a
scale translation KPS-ECOG in predictions based on equivalences table in Chapter 1,
a decimal rounding (rounding real numbers to the close integer value), and a tens
rounding (rounding integers modules of 10 to the closest tens number, only KPS
predictions). Therefore, we considered to overview the following cases of data pre-
dictions post-processing.
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(A) KPS prediction, decimal and non-tens rounding.
(B) KPS prediction, decimal and tens rounding.
(C) ECOG prediction, decimal and non-tens rounding.
(D) ECOG prediction, decimal and tens rounding of KPS prediction with posterior
translation to ECOG.
Since A and B scenarios consider the same prediction KPS scale, we established
comparisons among them based on the best experimental results found for all the
combinations of features [15296, 11472, 7648, 3824, 1912] within the best BOW repre-
sentations in ngram_ranges: (1, 1), (1, 2), and (1, 3) for both models, PLS and MLP
respectively.
Algorithm Ngram Features (A)1− R2min (B)1− R2min (A)1− R2max (B)1− R2max
PLS 1, 1 15 296 1.001 1.029 1.056 1.098
PLS 1, 2 1912 1.017 1.046 1.028 1.055
PLS 1, 3 1912 1.013 1.037 1.038 1.062
MLP 1, 1 11 472 1.002 1.001 1.005 1.158
MLP 1, 2 11 472 1.002 1.001 1.005 1.158
MLP 1, 3 11 472 1.002 1.001 1.005 1.158
TABLE 4.7: Comparisons among best configurations in 10-CV testing
1− R2 at A and B Text Vectorization data representations in PLS and
MLP.
Algorithm Ngram Features (A)MSEmin (B)MSEmin (A)MSEmax (B)MSEmax
PLS 1, 1 15 296 299.520 307.698 251.534 261.595
PLS 1, 2 1912 304.025 312.942 244.890 251.252
PLS 1, 3 1912 302.993 310.053 247.241 253.040
MLP 1, 1 11 472 299.643 299.335 239.352 275.702
MLP 1, 2 11 472 299.643 299.335 239.352 275.702
MLP 1, 3 11 472 299.643 299.335 239.352 275.702
TABLE 4.8: Comparisons among best configurations in 10-CV testing
MSE at A and B Text Vectorization data representations in PLS and
MLP.
After experimenting, we found that the most accurate form to refine predictions in
terms of 1− R2 and MSE scores is A: KPS prediction, decimal and non-tens round-
ing. In order to clarify tens rounding let us denote it as the rounding of modules of
10 integers to the closest tens number.
After that, we can infer that for KPS prediction tens rounding refining is not useful
for obtaining more accurate predictions in both linear and non-linear models.
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Since C and D cases consider ECOG predictions, we established comparisons among
them based on the best experimental results found for all the combinations of fea-
tures [15296, 11472, 7648, 3824, 1912]within the best BOW representations in ngram_ranges:
(1, 1), (1, 2), and (1, 3) for both models, PLS and MLP respectively.
Algorithm Ngram Features (C)1− R2min (D)1− R2min (C)1− R2max (D)1− R2max
PLS 1, 1 1912 1.160 1.169 1.200 1.104
PLS 1, 2 15 296 1.122 1.135 1.213 1.107
PLS 1, 3 1912 1.131 1.130 1.209 1.126
MLP 1, 1 11 472 1.201 1.201 1.117 1.117
MLP 1, 2 11 472 1.201 1.201 1.117 1.117
MLP 1, 3 11 472 1.201 1.201 1.117 1.117
TABLE 4.9: Comparisons among best configurations in 10-CV testing
1− R2 at C and D Text Vectorization data representations in PLS and
MLP.
Algorithm Ngram Features (C)MSEmin (D)MSEmin (C)MSEmax (D)MSEmax
PLS 1, 1 1912 0.996 1.004 0.696 0.641
PLS 1, 2 15 296 0.964 0.975 0.704 0.643
PLS 1, 3 1912 0.971 0.970 0.702 0.653
MLP 1, 1 11 472 1.031 1.031 0.648 0.648
MLP 1, 2 11 472 1.031 1.031 0.648 0.648
MLP 1, 3 11 472 1.031 1.031 0.648 0.648
TABLE 4.10: Comparisons among best configurations in 10-CV test-
ing MSE at C and D Text Vectorization data representations in PLS and
MLP.
After the experiment and a review of the 1− R2 & MSE scores, we can conclude that
D, a KPS prediction with decimal and tens rounding translated to ECOG bring a
better learning performance than C, a natural ECOG prediction without tens round-
ing.
For this reason, we can infer that predicting KPS and a posterior translation to ECOG
seem to be more feasible in terms of learning than learning ECOG responses and pre-
dict them. All this seems to be related to the fact that higher range scales overcome
in certain form the data response unbalance. In highlights, that in this particular
application samples have a unbalanced distribution.
4.5 Experimenting without Problematic Sample Cases
After performing the experiments related to post-processing data predictions, we
considered keeping the most profitable approaches to refine predictions, A and D.
44 Chapter 4. Experiments
Furthermore, we considered to overview another potential improvement related to
generalization of models. We considered a samples splitting according to the com-
patibility degree criteria in ranges proposed in this work assessing how close is the
prediction in terms of ranges of values comparisons. The compatibility criteria as-
sumption is based on the following mathematical expression:
CD(yi, yˆi) = 1.0 ∗ length(get_scales(max(yi,min, ˆyi,min), min(yi,max, ˆyi,max)))length(get_scales(min(yi,min, ˆyi,min), max(yi,max, ˆyi,max)))
where:
i : index of i-th sample.
yi : i-th response values (min and max).
yˆi : i-th predicted response values (min and max).
CD() : compatibility degree function among two ranges.
length() : number of stages in the range.
getscales() : generation of range stage list by min and max values.
max() : maximum value of a list of numbers.
min() : minimum value of a list of numbers.
yi,min : i-th (KPS/ECOG) min response value.
yi,max : i-th (KPS/ECOG) max response value.
ˆyi,min : i-th (KPS/ECOG) min response predicted value.
ˆyi,max : i-th (KPS/ECOG) max response predicted value.
Furthermore, we considered this criteria as an alternative informative metric to as-
sess how close are the predictions to response variables considering both min and
max range of predictions.
Interestingly, after performed a manual Microsoft Excel analysis of this compatibil-
ity criteria values, we decided to split dataset samples by CD <= 0.25 threshold
criteria. Consequently, we found that the lower CD split samples that represent the
most problematic are featured by lower bounding range response KPS/ECOG val-
ues and mono KPS/ECOG values (i.e. ranges where response variables min, max
have the same value).
On the other hand, we found that the higher CD split featured by higher ranges
in response comprise 94% of the samples from the Full− Set. Therefore, 6% of prob-
lematic cases can be discard as not having a statistical relevance from the population
of samples.
Consequently we may consider the fact that lower CD samples increase noise at
build a general model including the complete set of samples. Based on the previous
fact, we put aside the 256 problematic samples to evaluate the 3, 767 samples related
to the CD > 0.25 trying to observe how does this data sub setting result at the model
learning.
The following experiments intend to establish comparisons among the 3, 767 and
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4, 023 samples sizes considering A-KPS prediction and D-ECOG prediction previously
selected at Prediction Refining section. For differentiation purposes in terms of how
difficult may result build each model, we must describe the variances that each of
the datasets have in KPS & ECOG scales for min & max scores in the prediction task.
(I) Complete set of samples (4, 023 samples)
Scale min max
KPS 298.939 238.065
ECOG 0.858795 0.580649
TABLE 4.11: Complete set of samples (I): ECOG and KPS response
variables variances.
(II) Non-problematic set of samples (3, 767 samples)
Scale min max
KPS 158.615783 47.333426
ECOG 0.407559 0.115017
TABLE 4.12: Non-problematic set of samples (II): ECOG and KPS re-
sponse variables variances.
Algorithm Ngram Features (I)1− R2min (I I)1− R2min (I)1− R2max (I I)1− R2max
PLS 1, 1 15 296 1.001 0.916 1.056 1.016
PLS 1, 2 1912 1.017 0.931 1.028 0.984
PLS 1, 3 1912 1.013 0.931 1.038 0.989
MLP 1, 1 11 472 1.002 1.000 1.005 0.999
MLP 1, 2 11 472 1.002 1.000 1.005 0.999
MLP 1, 3 11 472 1.002 1.000 1.005 0.999
TABLE 4.13: Best Testing 10-CV 1− R2 for Text Vectorization without
SVD projections for (I) and (II) sets of samples at A (KPS) prediction
refine for PLS and MLP.
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Algorithm Ngram Features (I)MSEmin (I I)MSEmin (I)MSEmax (I I)MSEmax
PLS 1, 1 15 296 299.520 145.446 251.534 48.102
PLS 1, 2 1912 304.025 147.693 244.890 46.608
PLS 1, 3 1912 302.993 147.714 247.241 46.849
MLP 1, 1 11 472 299.643 158.618 239.352 47.330
MLP 1, 2 11 472 299.643 158.618 239.352 47.330
MLP 1, 3 11 472 299.643 158.618 239.352 47.330
TABLE 4.14: Best Testing 10-CV MSE for Text Vectorization without
SVD projections for (I) and (II) sets of samples at A (KPS) prediction
refine for PLS and MLP.
Algorithm Ngram Features (I)1− R2min (I I)1− R2min (I)1− R2max (I I)1− R2max
PLS 1, 1 1912 1.169 1.356 1.104 1.086
PLS 1, 2 15 296 1.135 1.351 1.107 1.093
PLS 1, 3 1912 1.130 1.408 1.126 1.086
MLP 1, 1 11 472 1.201 1.775 1.117 1.086
MLP 1, 2 11 472 1.201 1.775 1.117 1.086
MLP 1, 3 11 472 1.201 1.775 1.117 1.086
TABLE 4.15: Best Testing 10-CV 1− R2 for Text Vectorization without
SVD projections for (I) and (II) sets of samples at D (ECOG) prediction
refine for PLS and MLP.
Algorithm Ngram Features (I)MSEmin (I I)MSEmin (I)MSEmax (I I)MSEmax
PLS 1, 1 1912 1.004 0.552 0.641 0.125
PLS 1, 2 15 296 0.975 0.550 0.643 0.125
PLS 1, 3 1912 0.970 0.574 0.653 0.125
MLP 1, 1 11 472 1.031 0.723 0.648 0.125
MLP 1, 2 11 472 1.031 0.723 0.648 0.125
MLP 1, 3 11 472 1.031 0.723 0.648 0.125
TABLE 4.16: Best Testing 10-CV MSE for Text Vectorization without
SVD projections for (I) and (II) set of samples at D (ECOG) prediction
refine for PLS and MLP.
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After performing the experiments, we found that MSE and 1− R2 scores are mini-
mized in the particular scenario of A KPS prediction refining of models learning in
set without problematic samples.
Notably, set without problematic samples has a lower variance for min and max
response variables compared to the complete set of samples as it can be seen in Table
4.11 and 4.12. Therefore, as it was shown in previous results in order to optimize
(maintain or decrease) 1− R2 scores it is required to obtain lower MSE.
This fact suggest that for the particular case of A KPS prediction refining considering
a subset of samples without problematic cases result more profitable than using the
complete set of samples.
On the other hand, in the particular case of D ECOG prediction refining, we found
that for the complete set samples learning MSE are higher than set without problem-
atic samples. Besides, as it was previously seen in Tables 4.11 and Tables 4.12 response
variable variances in complete set of samples are higher than set of samples without
problematic cases. As an additional fact, 1− R2 scores in the complete set are lower
than set without problematic samples.
This fact suggests MSE scores related to the set without problematic samples sce-
nario are not low enough in relation with their response variables variances. For
this reason, in the particular case of predicting D ECOG prediction refining, a com-
plete set of samples have to be considered.
Moreover, despite the fact that prediction errors MSE in both Predictions Refining
approaches A and D are not comparable since predictions are in different scales.
We found that approach A, which represents a KPS prediction without tens round-
ing seem to be more profitable than approach D that considers a tens rounding in
KPS prediction with a posterior ECOG scale translation in terms minimizing 1−R2.
After analyzing prediction results without problematic cases we decided to keep
only the set without problematic samples, which represent the 94% of samples from
the entire dataset for predicting KPS.
Furthermore, after experimentation on D ECOG predicting refining, we decided to
perform ECOG learning with the complete set of samples. Summing up, we selected
the following partitions refining with their most suitable representation of the data
for further experiments:
• KPS prediction, decimal and non-tens rounding in set without problematic
samples.
• ECOG prediction, decimal and tens rounding of KPS prediction with posterior
translation to ECOG in complete set.
After that, going further with the best results obtained with Text Vectorization without
SVD, we proceed assessing results considering SVD projections and we found the
following experimental results:
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Algorithm Ngram Features 1− R2min 1− R2max MSEmin MSEmax
PLS 1, 1 252 0.907 0.976 143.987 46.205
PLS 1, 2 252 0.897 0.962 142.356 45.559
PLS 1, 3 252 0.898 0.969 142.483 45.866
MLP 1, 1 63 0.957 1.055 151.798 49.965
MLP 1, 2 63 0.953 1.108 151.274 52.490
MLP 1, 3 63 0.935 1.037 148.441 49.113
TABLE 4.17: Best Testing 10-CV 1−R2 and MSE for (II) set of samples
with Text Vectorization and SVD projections in A (KPS) predictions
refining for PLS and MLP.
Algorithm Ngram Features 1− R2min 1− R2max MSEmin MSEmax
PLS 1, 1 252 1.130 1.109 0.971 0.644
PLS 1, 2 503 1.087 1.074 0.934 0.624
PLS 1, 3 252 1.089 1.098 0.935 0.638
MLP 1, 1 63 1.190 1.147 1.022 0.666
MLP 1, 2 63 1.165 1.121 1.001 0.651
MLP 1, 3 63 1.164 1.151 1.000 0.668
TABLE 4.18: Best Testing 10-CV 1− R2 and MSE for (I) set of samples
with Text Vectorization and SVD projections in D (ECOG) predictions
refining for PLS and MLP.
As a removal of problematic samples experiment conclusion, we found that data
predictions seem to generalize in more accurate way over KPS scale. Additionally,
we can observe that in KPS predictions PLS models generalize better for 252 fea-
tures size approximation for every ngram_range considered. On the other hand,
MLP generalize better under lower features size approximation as 63.
Moreover, this results denote an improvement in comparison with all the results
obtained for KPS predictions in Chpater 5: Simulations.
This conclusion considers the fact that even if the samples of data are 6% less, and
min and max scores variances are lower, errors have decreased considerably in rela-
tion with the lower variance of the response variables from the 94% of the samples,
leading to optimum values 1− R2 and MSE found in all the experimentations.
Notably, ECOG prediction MSE require a more deep review based on the fact of
lower scale ranges and units in comparison than KPS scale and units. Considering
that lower MSE values may not represent good approximations and accurate mod-
els in ECOG predictions.
4.6 Model Selection configurations
After multiple considerations related to the data representations, predictions refin-
ing, and removing of problematic samples, we proceed trying to find optimum re-
sults by selecting the best parametric configuration of the models implemented in
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this work. Remarkably, as we observed in previous sections, KPS prediction seem to
be a more suitable task based on the results obtained in comparison to ECOG pre-
dictions results. Therefore, we are going to proceed with models tuning only consid-
ering the KPS prediction with decimal and non-tens rounding with set of samples
without problematic cases. Consequently, we are going to leave aside ECOG predic-
tions for future work. In short we are going to overview the final results obtained
representing the best configurations found of each model.
4.6.1 Partial Least Squares (PLS)
To remark, experiments related to different PLS configurations are found in Appendix
C.1 Partial Least Squares Results. These experiments comprise the following parame-
ters:
• PLS number of components: [1, 2, 3, 4, 5, 10, 20, 50].
• PLS normalizations values: [False, True].
• Features representations as ngramrange lemmas: [(1, 1), (1, 2), (1, 3)].
• SVD number of features mappings:
[500, 450, 400, 350, 300, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 100, 50].
After looking at the results in Appendix C.1, we found that PLS number of compo-
nents seem to have an inversely proportional relation with the number of features
used. The higher number of components is correlated with lower number of features
required.
Furthermore, after performing simulations with different number of components
in the PLS algorithm as previously mentioned, we established comparisons among
PLS normalization parameter in either 0 : False or 1 : True values. And we obtained
the following concluding results for 1− R2 at min and max KPS predictions.
PLSComponents ngram_combination Features Norm = 1 Norm = 0
1 1, 2 240 0.8970 0.9331
2 1, 2 240 0.8874 0.8967
3 1, 3 240 0.8873 0.8834
4 1, 3 200 0.8943 0.8883
5 1, 3 200 0.8927 0.8847
10 1, 3 200 0.8926 0.8900
20 1, 3 200 0.8926 0.8924
50 1, 3 200 0.8924 0.8926
TABLE 4.19: KPSmin : 1 − R2 for different PLS components,
ngramrange and number of features configurations.
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PLSComponents ngram_combination Features Norm = 1 Norm = 0
1 1, 3 400 0.9650 1.0130
2 1, 3 350 0.9550 0.9811
3 1, 2 250 0.9495 0.9717
4 1, 2 250 0.9579 0.9577
5 1, 2 250 0.9571 0.9637
10 1, 2 250 0.9561 0.9597
20 1, 2 250 0.9583 0.9565
50 1, 2 240 0.9592 0.9594
TABLE 4.20: KPSmax : 1 − R2 for different PLS components,
ngramrange and number of features configurations.
After all the experimentation, related to PLS tuning on KPS predictions, we can con-
clude that the best PLS configurations found for this type of prediction are:
1. KPS-PLS 1− R2min = 0.8834
• components = 3
• normalization = False
• ngram_combination = (1, 3)
• SVD f eatures = 240
2. KPS-PLS 1− R2max = 0.9495
• components = 3
• normalization = True
• ngram_combination = (1, 2)
• SVD f eatures = 250
Based on the concluding results of min and max for each different type of predic-
tion KPS. We found that each response variable to be predicted min and max are
minimized by the PLS model in different configurations of ngramrange and number
of features. Although, the number of components in the PLS algorithm in the best
results obtained for each prediction are the same. This may suggest that the task
considered seem to be tough to model and that improving results seem to be re-
lated with the data representations and considerations than with a bi factorial linear
model as PLS.
4.6.2 Multilayer Perceptron (MLP)
In order to reference properly to the experiments related to different MLP configura-
tions, these experimental simulations are found in Appendix C.2 Multilayer Perceptron
Results. The experiments comprise the following parameters:
• MLP number of neurons: [2, 5, 7, 10, 15, 25].
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• MLP number of epochs: [5, 10, 25, 50, 75, 100].
• MLP activation functions: identity, logistic, tanh, and relu.
• MLP α value: 1x10−3.
• MLP solver: lbfgs.
• Features representations as ngramrange lemmas: [(1, 1), (1, 2), (1, 3)].
• SVD number of features mappings:
[500, 450, 400, 350, 300, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 100, 50].
After looking at the results in Appendix C.2, we found that MLP activations func-
tions show a generalized behavior at predicting KPSmin, in which most of the neu-
rons configurations require higher number of epochs in comparison with neurons
configurations at predicting KPSmax. Furthermore, particularly, we can observe that
in KPSmax predictions lower number of neurons result in higher number of epochs
and vice versa. On the other hand, in KPSmin in general for all the configurations of
neurons it is required a constant value of epochs in most of the cases.
Additionally, we devoted some time to describe in some way the fluctuation founded
by each MLP activation function at their KPSmin, KPSmax predictions 1− R2 perfor-
mance score. Based on Appendix C.2 tables we obtained the minimum and maximum
feature size per tables, obtained the range, as range = max−min and consequently
calculating the average of (1, 1), (1, 2), (1, 3) related to each activation function for
both of the 1− R2min and 1− R2max values.
f eatures_range_size identity logistic tanh relu
1− R2min 223.3 220.0 243.3 190.0
1− R2max 206.6 176.6 166.6 276.6
TABLE 4.21: Fluctuation analysis based on 1 − R2min and 1 − R2max
f eatures_range_size of tables shown in Appendix C.2 for different
ngramcombinations, f eature_size configuration considering identity,
logistic, tanh and relu activation functions.
Furthermore, after a brief analysis of the average features range size, we found that
identity and logistic activation functions have a more consistent behavior among
the feature range sizes of both of the scores in comparison to tanh and relu that have
lower feature ranges for one score, and higher for others. Therefore, this may sug-
gest that having less fluctuations identity and logistic seem to have a slightly more
wide and focalized weight optimization space compared to tanh and relu. Besides,
the fact may also suggest that tuning both functions by different parameters may
show a consistent path by different combinations of parameters.
In addition, after performing simulations with different number of components in
the MLP algorithm as previously mentioned, we established comparisons among
MLP parameters for each activation function, in order to find the best configuration
of each activation function. Consequently, we obtained the following concluding
results for 1− R2 at min and max KPS predictions.
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Neurons Epochs ngram_combination Features 1− R2min
2 100 1, 3 210 0.8985
5 100 1, 2 500 0.9022
7 100 1, 3 220 0.8965
10 100 1, 3 240 0.8903
15 100 1, 3 190 0.8931
25 100 1, 2 500 0.9009
TABLE 4.22: KPSmin : 1− R2 for best MLP (neurons, epochs) and α =
1x10−3 configurations with identity activation function in different
ngramrange and number of features combinations.
Neurons Epochs ngram_combination Features 1− R2max
2 50 1, 3 500 0.9794
5 50 1, 2 180 0.9746
7 25 1, 2 190 0.9785
10 100 1, 2 240 0.9668
15 25 1, 2 350 0.9817
25 25 1, 3 180 0.9807
TABLE 4.23: KPSmax : 1− R2 for best MLP (neurons, epochs) and α =
1x10−3 configurations with identity activation function in different
ngramrange and number of features combinations.
Neurons Epochs ngram_combination Features 1− R2min
2 75 1, 3 180 0.8951
5 75 1, 2 450 0.9004
7 75 1, 3 190 0.8965
10 75 1, 3 220 0.9040
15 75 1, 3 200 0.9179
25 75 1, 3 200 0.9052
TABLE 4.24: KPSmin : 1 − R2 for best MLP (neurons, epochs) and
α = 1x10−3 configurations with logistic activation function in differ-
ent ngramrange and number of features combinations.
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Neurons Epochs ngram_combination Features 1− R2max
2 100 1, 2 230 0.9916
5 50 1, 2 100 0.9852
7 50 1, 2 220 0.9689
10 50 1, 2 250 0.9800
15 25 1, 2 210 0.9999
25 25 1, 2 190 0.9842
TABLE 4.25: KPSmax : 1 − R2 for best MLP (neurons, epochs) and
α = 1x10−3 configurations with logistic activation function in differ-
ent ngramrange and number of features combinations.
Neurons Epochs ngram_combination Features 1− R2min
2 50 1, 2 220 0.9256
5 50 1, 3 350 0.9324
7 75 1, 3 100 0.9726
10 50 1, 2 220 0.9235
15 50 1, 2 210 0.9226
25 10 1, 2 230 1.0000
TABLE 4.26: KPSmin : 1 − R2 for best MLP (neurons, epochs) and
α = 1x10−3 configurations with tanh activation function in different
ngramrange and number of features combinations.
Neurons Epochs ngram_combination Features 1− R2max
2 50 1, 3 250 0.9879
5 10 1, 1 350 0.9981
7 50 1, 2 210 0.9965
10 10 1, 2 230 0.9845
15 10 1, 2 210 0.9945
25 10 1, 2 200 0.9999
TABLE 4.27: KPSmax : 1 − R2 for best MLP (neurons, epochs) and
α = 1x10−3 configurations with tanh activation function in different
ngramrange and number of features combinations.
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Neurons Epochs ngram_combination Features 1− R2min
2 100 1, 2 350 0.9056
5 100 1, 2 400 0.8944
7 100 1, 3 250 0.9013
10 100 1, 3 230 0.9010
15 100 1, 3 190 0.8934
25 100 1, 2 210 0.9008
TABLE 4.28: KPSmin : 1 − R2 for best MLP (neurons, epochs) and
α = 1x10−3 configurations with relu activation function in different
ngramrange and number of features combinations.
Neurons Epochs ngram_combination Features 1− R2max
2 25 1, 2 240 0.9906
5 25 1, 1 500 0.9844
7 25 1, 3 200 0.9654
10 25 1, 2 400 0.9770
15 25 1, 2 100 0.9855
25 100 1, 2 250 0.9710
TABLE 4.29: KPSmax : 1 − R2 for best MLP (neurons, epochs) and
α = 1x10−3 configurations with relu activation function in different
ngramrange and number of features combinations.
After all the experimentation, related to MLP tuning on KPS predictions, we can
conclude that the best MLP configurations found for this type of prediction are:
1− R2 Score identity logistic tanh relu
KPSmin 0.8903 0.8951 0.9226 0.8934
KPSmax 0.9668 0.9689 0.9845 0.9654
TABLE 4.30: Best Testing 10-CV 1− R2 from all configurations con-
sidered in identity, logistic, tanh, and relu in MLP activation functions.
Notably, considering that the identity MLP activation function mimics the same be-
havior as Multivariate Linear Regression, a linear method for inducing data, we must
conclude that the best non-linear configuration of the MLP comes with logistic ac-
tivation function based on the results shown in Table 4.30, and in the consistency
behavior among the KPS 1− R2min and 1− R2max feature range size analysis in Table
4.21.
For a informative description of the MLP best parameters, the best MLP parame-
ters found are:
1. KPS-PLS 1− R2min = 0.8951
• activation_ f unction = logistic
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• solver = lb f gs
• α = 1x10−3
• neurons = 2
• epochs = 75
• ngram_combination = (1, 3)
• SVD f eatures = 180
2. KPS-PLS 1− R2max = 0.9689
• activation_ f unction = logistic
• solver = lb f gs
• α = 1x10−3
• neurons = 7
• epochs = 50
• ngram_combination = (1, 2)
• SVD f eatures = 220
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Closing Results
In this section we are going to describe in a brief way the considerations that were
done in order to find the final and conclusive results show further in the current
chapter. As it was seen in Section 4.2: Text Vectorization for this particular BreastCancer
CTCP task we conclude that simple ngramrange configurations in text vectorization
lead to minimize 1− R2 and MSE scores. This fact considers features representa-
tions as combinations of one lemma with two, or three lemmas.
Furthermore, as it was mentioned in Section 4.3: Data Projections applying SVD
projections over data vectorization, seem to be consequent with metrics minimiza-
tion over simple ngramrange configurations. This fact enforces the idea of simple
ngramrange configurations (1, 1), (1, 2), (1, 3) as a path to follow to optimize learning
predictions. Additionally, we conclude that both models seem to generalize better
in SVD projections with approximately 250 mapped features.
Moreover, as it was seen in Section 4.4: Prediction Refining, we found that the most
accurate form to refine predictions in terms of minimizing 1− R2 and MSE scores
is considering a KPS prediction with decimal rounding and without tens rounding
(rounding modules of 10 values to the closest 10 multiple). Notably, we found that
predicting ECOG scores may result hard for inducing the models based on their
smaller scale range of values and the unbalanced dataset considered in this appli-
cation. For this reason, we do not extend any closing result for ECOG scale, and
resulting predictions closing metrics are related to KPS scale.
Additionally, as it was mentioned in Section 4.5: Experimenting without Problematic
Sample Cases, removal of problematic samples from dataset showed that models
seem to generalize in more accurate way, particularly, on KPS predictions, show-
ing an improvement in 1 − R2 and MSE scores minimization in comparison with
the results obtained in previous stages of the experimentation.
We found that problematic samples related to CT have a proper and accurate length
of text but comprise cases in which, clinical trial KPS profile is featured by lower
ranges (i.e. in which often the maximum value of the range is lower than 60 accord-
ing to KPS scale) and cases in which prediction is related to a single value (i.e. in
which minimum and maximum values of the KPS range comprise the same value).
For the sake of a clarifying the problematic samples, response variables min, and
max of problematic samples are found in Appendix D.
To sum up, this conclusion suggests that removed samples of data consisting in 6%
are not statistically relevant in comparison with the 94%. Besides, we found that
even when considering 94% of the samples comprise a min and max response scores
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lower variance, the errors have decreased considerably in relation with the variance
of the response variables leading to the minimal 1 − R2 found in all the previous
experimentations.
Finally, as we conclude in Section 4.6: Model Selection after experimenting with dif-
ferent configurations among the linear and non-linear models, we obtained the fol-
lowing closing results. After all the experimentation on linear models related to PLS
tuning on KPS predictions, we can conclude that the best PLS configurations found
for this type of prediction are:
1. KPS-PLS 1− R2min = 0.8834
• components = 3
• normalization = False
• ngram_combination = (1, 3)
• SVD f eatures = 240
2. KPS-PLS 1− R2max = 0.9495
• components = 3
• normalization = True
• ngram_combination = (1, 2)
• SVD f eatures = 250
Moreover, after all the experimentation done with non-linear models, must conclude
that the best configuration of the MLP comes with logistic activation function based
on the results shown in Table 4.30, and in the consistency behavior among the KPS
1− R2min and 1− R2max feature range size analysis in Table 4.21.
For a informative description of the MLP best parameters, the best MLP parameters
found are:
1. KPS-PLS 1− R2min = 0.8951
• activation_ f unction = logistic
• solver = lb f gs
• α = 1x10−3
• neurons = 2
• epochs = 75
• ngram_combination = (1, 3)
• SVD f eatures = 180
2. KPS-PLS 1− R2max = 0.9689
• activation_ f unction = logistic
• solver = lb f gs
• α = 1x10−3
• neurons = 7
• epochs = 50
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• ngram_combination = (1, 2)
• SVD f eatures = 220
Furthermore, for effects of comparison between the learning and the testing learning
performance we describe the final outcomes of the simulations of PLS and MLP. We
take into account as it was previously mentioned in Chapter 4: Experimentation, that
in every model best configuration of prediction related to min and max comprise
different configurations of the model for both of the response variables predictions.
Finally let us establish a learning comparison in terms of 1 − R2 and MSE scores
from 10 Fold Cross Validation training and testing in both models.
learning_task 1− R2min 1− R2max MSEmin MSEmax
Training 0.7766 0.8123 123.1852 38.4503
Testing 0.8834 0.9495 140.1356 44.9453
TABLE 5.1: Learning comparison in terms of 1− R2 and MSE scores
from 10 Fold Cross Validation training and testing in PLS best configu-
rations.
learning_task 1− R2min 1− R2max MSEmin MSEmax
Training 0.798 150 0.937 983 126.599 226 44.397 935
Testing 0.895 134 0.968 871 141.982 402 45.859 968
TABLE 5.2: Learning comparison in terms of 1− R2 and MSE scores
from 10 Fold Cross Validation training and testing in MLP best config-
urations.

61
Chapter 6
Conclusions
As we can observe from all the researching, experimentation and work done in this
thesis, The Breast Cancer Clinical Trial ECOG-Classification Problem has many relevant
aspects that have to be considered in order to find a proper representation of the
data to train a model.
We can start describing the data used in the experiments as small source of clini-
cal trials for breast cancer, we found that now a days the number of breast cancer
clinical trials around the world is relatively smaller, comprising less than ten thou-
sand samples. Most of the samples, do not have the relevant information in terms of
ECOG or KPS scales scores to be considered in learning experiments, this fact make
the classification learning task a hard to model task by insufficient amount of data.
Furthermore, after gathering the samples and keeping only the ones that have PS
scale scores as ECOG, KPS or others, we found that the range of values considered
as response variables, were unbalanced in terms of minimum, maximum or range
in ECOG or KPS scorings. After this, we decided to move forward to a prediction
representation of the task and rely on the natural numerical property of the values
in PS scales, keeping only the maximum and minimum score and turn the problem
into a multivariate regression task.
Furthermore, besides the data considerations and the approaching solution, we can
observe from the work done, that Natural Language Processing has considerable im-
portance by the fact as it was shown at the experimental results a proper representa-
tion of the features as combinations of lemmas, and an appropriate feature size are
highly correlated with a discriminant representation of the data. For this particular
instance of breast cancer clinical trial analysis, we found that a proper represen-
tation of the features involves stop words removal removing non-relevant terms,
lemmatization finding the root form of English medical terms, and text vectoriza-
tion representing data features characterized by relatively simple combinations of
lemmas, containing combinations of 1 lemma with 2 or 3 lemmas. Besides, another
relevant characteristic related to data representation is feature size that after all the
experimentation we found that a useful approximation of numbers of features is
given by 250 attributes in data, that in our case are represented as meta-features.
These meta-features are projections of the original features for compressing the data
dimensions and keeping most of the data variance applying SVD feature selection
frameworks. Finally, there were additional conditions considered as prediction re-
fining and removal of problematic cases that increase the learning performance in
the experiments.
In addition, related to Machine Learning algorithms, we can observe that models are
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sensible to their parameters combination, in particular Multilayer perceptron (MLP)
that comprises more parameters compared to Partial Least Squares (PLS). Besides, we
can conclude from the experimental results obtained that models behaviors and best
results are congruent approximately with the initial configurations from the begin-
ning of the experimentations. This may suggest that data representations may have
more relevance than the algorithms tuning. Besides, we can observe that models
behavior do not easily generalize well on both KPS scores using the same data con-
siderations. Every model has slightly different data representations configurations
to achieve better results at min and max scores in predictions. This fact suggests that
the multivariate prediction task has certain difficulty in terms of predicting results
of two variables with considerably different variances.
Finally we can observed from the closing experimental results that both models,
achieve reasonable good scores in 1− R2 and MSE metrics, after establishing com-
parisons with among Training and Testing results obtained. These results denoted
that scores in metrics are relatively close in both learning simulations, this may sug-
gest that the Testing results are approximately close to the optimal results that can be
found for this particular task with the conditions previously mentioned. Besides, we
can conclude that for this particular type of problem related to Breast Cancer CT, and
by all the technical and theoretical specifications done, linear models as PLS have an
simple and accurate learning performance than non-linear models as MLP.
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Appendix A
Clinical Trial Examples
In this section we show two different types of breast cancer CT XML files: the ones
with explicit ECOG/KPS score and the ones without ECOG/KPS score. In order to
clarify, the XML highlighted fields with scores represent the medical text used in the
experiments.
A.1 Example of Explicit ECOG Score in Clinical Trial
<?xml version="1.0" encoding="UTF-8"?>
<?
This xml conforms to an XML Schema at: https://clinicaltrials.gov/ct2/
html/images/info/public.xsd and an XML DTD at: https://
clinicaltrials.gov/ct2/html/images/info/public.dtd
?>
<clinical_study rank="2051" >
<required_header>
<download_date>
ClinicalTrials.gov processed on November 16, 2016
</download_date>
<link_text>
Link to the current ClinicalTrials.gov record.
</link_text>
<url>https://clinicaltrials.gov/show/NCT00188604</url>
</required_header>
<id_info>
<org_study_id>UHN REB 03-0741-C</org_study_id>
<nct_id>NCT00188604</nct_id>
</id_info>
<brief_title>
The Use of Selenium to Treat Secondary Lymphedema - Breast
Cancer
</brief_title>
<official_title>
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A Randomized Phase II Placebo-controlled Double Blind Study of
Using Selenium in the Treatment of Secondary Lymphedema in
Breast Cancer Patients
</official_title>
<sponsors>
<lead_sponsor>
<agency>University Health Network, Toronto</agency>
<agency_class>Other</agency_class>
</lead_sponsor>
<collaborator>
<agency>Princess Margaret Hospital, Canada</agency>
<agency_class>Other</agency_class>
</collaborator>
</sponsors>
<source>University Health Network, Toronto</source>
<oversight_info>
<authority>Canada: Ethics Review Committee</authority>
</oversight_info>
<brief_summary>
<textblock>
The primary objective of this study to assess the
effectiveness of selenium compared to
placebo in reducing the lymphedema in-patients with
breast cancer. Secondary objectives are
to assess the impact of selenium on patient’s quality of
life and to assess the incidence of
adverse effects of selenium therapy.
</textblock>
</brief_summary>
<overall_status>Completed</overall_status>
<start_date>January 2004</start_date>
<completion_date type="Actual">January 2009</completion_date>
<primary_completion_date type="Actual">
January 2009
</primary_completion_date>
<phase>Phase 2</phase>
<study_type>Interventional</study_type>
<study_design>
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Allocation: Randomized, Endpoint Classification: Safety/Efficacy
Study, Intervention Model: Crossover Assignment, Masking:
Double-Blind, Primary Purpose: Treatment
</study_design>
<primary_outcome>
<measure>
To assess the effectiveness of orally administered
selenium compared to placebo in reducing arm
lymphedema in patients treated with surgery (axillary
nodal dissection) and radiotherapy for breast cancer
.
</measure>
</primary_outcome>
<secondary_outcome>
<measure>To assess the toxicity of selenium.</measure>
</secondary_outcome>
<secondary_outcome>
<measure>
To assess the association of selenium, quality of life
and limb function.
</measure>
</secondary_outcome>
<enrollment type="Anticipated">34</enrollment>
<condition>Breast Neoplasms</condition>
<condition>Lymphedema</condition>
<intervention>
<intervention_type>Drug</intervention_type>
<intervention_name>sodium selenite</intervention_name>
</intervention>
< eligibility >
< criteria >
< textblock >
- Patients with clinically documented lymphedema
of upper limb secondary to breast cancer
management (surgery - axillary nodal
dissection, and radiotherapy)
- Patients who have had other modalities of
management can be included, e.g. physical
therapy, pharmacological therapy
- ECOG performance 0-2
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- Informed consent
Exclusion Criteria:
- Active cellulitis/skin infection of the limb
- Venous thrombosis of the upper limbs
- Active malignancy
- Any other medical condition or congenital or
traumatic injury involving either limb
- Patients already on selenium medication
- Patients participating in another clinical
study related to lymphedema
</ textblock >
</ criteria >
<gender>Female</gender>
<minimum_age>18 Years</minimum_age>
<maximum_age>N/A</maximum_age>
<healthy_volunteers>No</healthy_volunteers>
</ eligibility >
<overall_official>
<last_name>Wilfred Levin, MD</last_name>
<role>Principal Investigator</role>
<affiliation>Princess Margaret Hospital, Canada</affiliation>
</overall_official>
<location>
<facility>
<name>Princess Margaret Hospital</name>
<address>
<city>Toronto</city>
<state>Ontario</state>
<zip>M5G 2M9</zip>
<country>Canada</country>
</address>
</facility>
</location>
<location_countries>
<country>Canada</country>
</location_countries>
<verification_date>August 2010</verification_date>
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<lastchanged_date>August 12, 2010</lastchanged_date>
<firstreceived_date>September 12, 2005</firstreceived_date>
<has_expanded_access>No</has_expanded_access>
<condition_browse>
<?
CAUTION: The following MeSH terms are assigned with an
imperfect algorithm
?>
<mesh_term>Breast Neoplasms</mesh_term>
<mesh_term>Lymphedema</mesh_term>
</condition_browse>
<intervention_browse>
<?
CAUTION: The following MeSH terms are assigned with an
imperfect algorithm
?>
<mesh_term>Selenious Acid</mesh_term>
<mesh_term>Sodium Selenite</mesh_term>
<mesh_term>Selenium</mesh_term>
</intervention_browse>
<? Results have not yet been posted for this study ?>
</clinical_study>
A.2 Example of Non-ECOG Score in Clinical Trial
<?xml version="1.0" encoding="UTF-8"?>
<?
This xml conforms to an XML Schema at: https://clinicaltrials.gov/ct2/
html/images/info/public.xsd and an XML DTD at: https://
clinicaltrials.gov/ct2/html/images/info/public.dtd
?>
<clinical_study rank="5360">
<required_header>
<download_date>
ClinicalTrials.gov processed on November 16, 2016
</download_date>
<link_text>
Link to the current ClinicalTrials.gov record.
</link_text>
<url>https://clinicaltrials.gov/show/NCT00558168</url>
</required_header>
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<id_info>
<org_study_id>ARI-IPEP-0104</org_study_id>
<nct_id>NCT00558168</nct_id>
</id_info>
<brief_title>
Electronic Study for Anastrozole Pharmacovigilance Evaluation
</brief_title>
<acronym>E-SAFE</acronym>
<official_title>
Electronic Study for Anastrozole Pharmacovigilance Evaluation
</official_title>
<sponsors>
<lead_sponsor>
<agency>AstraZeneca</agency>
<agency_class>Industry</agency_class>
</lead_sponsor>
</sponsors>
<source>AstraZeneca</source>
<oversight_info>
<authority>
Turkey: Turkish Republic Ministry of Health
</authority>
<has_dmc>No</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
Collecting information regarding adverse events from
patients on treatment with anastrazole
with early stage breast cancer
</textblock>
</brief_summary>
<overall_status>Completed</overall_status>
<start_date>January 2004</start_date>
<completion_date type="Actual">July 2008</completion_date>
<phase>N/A</phase>
<study_type>Observational</study_type>
<study_design>Time Perspective: Prospective</study_design>
<enrollment type="Actual">1850</enrollment>
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<condition>Early Breast Cancer</condition>
< eligibility >
< criteria >
< textblock >
Inclusion Criteria:
- Post-menopausal Early Invasive Breast Cancer
Patients who are under anastrazole treatment,
who have normal renal and hepatic functions.
Exclusion Criteria:
- Metastatic breast cancer patients, previous
hormonal therapy, other malignancies.
</ textblock >
</ criteria >
<gender>Female</gender>
<minimum_age>N/A</minimum_age>
<maximum_age>N/A</maximum_age>
<healthy_volunteers>No</healthy_volunteers>
</ eligibility >
<overall_official>
<last_name>Nejdet Uskent</last_name>
<role>Principal Investigator</role>
<affiliation>Kadir Has University Medical School</affiliation>
</overall_official>
<verification_date>July 2008</verification_date>
<lastchanged_date>July 25, 2008</lastchanged_date>
<firstreceived_date>November 13, 2007</firstreceived_date>
<keyword>Anastrazole</keyword>
<keyword>safety</keyword>
<keyword>early breast cancer</keyword>
<has_expanded_access>No</has_expanded_access>
<intervention_browse>
<? CAUTION: The following MeSH terms are assigned with an
imperfect algorithm ?>
<mesh_term>Anastrozole</mesh_term>
</intervention_browse>
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<? Results have not yet been posted for this study ?>
</clinical_study>
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Appendix B
Bag of Words Examples
B.1 BOW’s key features in ngram_range combinations
In this Appendix we are going to show the 25 most discriminant features (words)
from every ngram_range combination BOW considered in Chapter 4: Text Vectoriza-
tion Experiments. Terms are ordered by t f − id f score metric, which represent the
maximum metric value of the term from the 4, 023 complete set of samples.
ngram_range=(1, 1) ngram_range=(1, 2)
Term tf-idf Term tf-idf
old 1.0 hair 0.817760781
swogs 0.977048527 part 0.81684503
specified 0.925059629 soy 0.8108454
part 0.916463409 sibling 0.804823661
phase 0.908855313 step 0.766687391
spouse 0.895830064 phase 0.758143344
participant 0.890146639 prostatectomy 0.745085333
diabetic 0.88544224 fdr 0.73625407
step 0.874052591 nail 0.734587047
subject 0.870429308 hlaa 0.718011719
hair 0.80748843 participant 0.705056657
prostatectomy 0.805428139 swogs swogs 0.703875458
discontinuity 0.802834255 swogs 0.690414709
sonidegib 0.796083969 sonidegib 0.689348137
dca 0.786138212 inguinal 0.688492086
ulrr 0.779853429 gvhd 0.685998585
extranodal 0.777484271 reregistration 0.681479593
bwarm 0.772618304 psa 0.67637177
reregistration 0.770326621 arm 0.676176098
hlaa 0.767640101 subject ha 0.654713585
arm 0.767026005 ret 0.653799487
creat 0.765134332 specified 0.651336634
psa 0.763920221 cmv 0.642204536
mvabn 0.75910658 ulrr 0.63450361
normality 0.758882758 record 0.62805934
TABLE B.1: The most t f − id f discriminant features from
ngram_range (1, 1) and (1, 2) Text Vectorization.
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ngram_range=(1, 3) ngram_range=(2, 2)
Term tf-idf Term tf-idf
swogs 0.974902643 swogs swogs 0.994764112
hair 0.859718529 closed accrual 0.914707523
soy 0.810719505 subprotocol aim 0.872349524
part 0.791224417 oral vinorelbine 0.849146378
sibling 0.789594504 subject ha 0.803891806
step 0.780165803 participant ha 0.739818185
prostatectomy 0.752568507 physical activity 0.691454597
hlaa 0.727335025 participant must 0.681512334
participant 0.70793144 subject must 0.671062787
psa 0.706782034 since therapy 0.654498209
phase 0.698159361 patient ha 0.650439363
fdr 0.696680075 targeted tumor 0.637121131
subject ha 0.663776076 step patient 0.636834831
reregistration 0.660796746 epirubicin cyclophos-
phamide
0.635517485
arm 0.655003728 prior step 0.628799564
record 0.623042586 cancer eligible 0.625840882
octreotide 0.62204368 day cycle 0.624712314
yoga 0.60283539 targeting agent 0.622847026
ulrr 0.598120721 value upper 0.620934334
vinorelbine 0.589652565 step registration 0.613580576
sbrt 0.587545215 dose mvabn 0.611742069
specified 0.585900563 time unv 0.600528281
closed accrual 0.585666175 somatostatin analogue 0.597229692
participant ha 0.583020742 stage metastatic 0.591168519
lenalidomide 0.581676384 subject may 0.58667252
TABLE B.2: The most t f − id f discriminant features from
ngram_range (1, 3) and (2, 2) Text Vectorization.
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ngram_range=(2, 3) ngram_range=(3, 3)
Term tf-idf Term tf-idf
swogs swogs 0.996119143 age ecog performance 1.0
closed accrual 0.900508315 carcinoma head neck 1.0
subprotocol aim 0.84260866 swogs swogs swogs 0.995842077
subject ha 0.806135752 registration within wks 0.78140663
participant ha 0.752935778 disease requiring treat-
ment
0.755500359
physical activity 0.749988437 see disease characteris-
tic
0.750993309
epirubicin cyclophos-
phamide
0.716818304 start treatment day 0.742403015
targeted tumor 0.686087246 first line treatment 0.734258754
participant must 0.675858069 prior step registration 0.729432771
step patient 0.661033133 first day treatment 0.727607422
medical treatment 0.649489722 prior rmpdla injection 0.716119419
dose mvabn 0.635051663 value upper normal 0.710998888
subject must 0.627443852 line metastatic disease 0.707358049
stage metastatic 0.626074874 drink per day 0.702841002
patient ha 0.603925593 infiltrating ductal carci-
noma
0.702115072
day cycle 0.595454951 candidate receive ther-
apy
0.697875797
cancer biopsy 0.583260015 criterion patient breast 0.691854846
enrolled arm 0.577880944 providing informed
consent
0.686934287
standard treatment 0.573025084 prostate cancer patient 0.682326143
cancer eligible 0.561893099 uln reference lab 0.681195945
ineligible patient 0.548520723 chest wall breast 0.674908719
every week 0.548428036 start protocol therapy 0.670404778
arm patient 0.548387578 karnofsky performance
scale
0.669953553
preoperative
chemotherapy
0.545958711 exclusion criterion sig-
nificant
0.667812967
subject may 0.545662684 previous chemother-
apy treatment
0.665805647
TABLE B.3: The most t f − id f discriminant features from
ngram_range (2, 3) and (3, 3) Text Vectorization.
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Appendix C
Results in Models Tuning
C.1 Partial Least Squares Results
In this Appendix we are going to show the results obtained by simulating the ML
algorithms with different parametric configurations.
Features 1C 2C 3C 4C 5C 10C 20C 50C
400 0.9231 0.9133 0.9233 0.9363 0.9419 0.9351 0.9344 0.9352
350 0.9224 0.9097 0.9168 0.9308 0.9318 0.9192 0.9194 0.9217
300 0.9238 0.9144 0.9178 0.9330 0.9319 0.918 0.9185 0.9203
250 0.9141 0.9051 0.9081 0.9185 0.9174 0.9086 0.9088 0.9086
240 0.9178 0.9078 0.9082 0.9170 0.9151 0.9057 0.9054 0.9047
230 0.9172 0.9078 0.9114 0.9221 0.9192 0.9111 0.9112 0.9115
220 0.9168 0.9056 0.9092 0.9170 0.9156 0.9078 0.9077 0.9085
210 0.9120 0.9062 0.9079 0.9139 0.9157 0.9070 0.9070 0.9069
200 0.9151 0.9055 0.9071 0.9137 0.9132 0.9059 0.9061 0.9060
190 0.9116 0.9021 0.9020 0.9098 0.9075 0.9007 0.9008 0.9010
180 0.9103 0.9001 0.9018 0.9017 0.9024 0.8973 0.8974 0.8964
170 0.9125 0.9040 0.9069 0.9104 0.9117 0.9047 0.9048 0.9030
160 0.9175 0.9061 0.9097 0.9123 0.9118 0.9076 0.9077 0.9064
150 0.9238 0.9155 0.9178 0.9235 0.9214 0.9160 0.9158 0.9168
100 0.9294 0.9224 0.9217 0.9243 0.9216 0.9194 0.9196 0.9196
50 0.9390 0.9335 0.9326 0.9341 0.9322 0.9319 0.9319 0.9316
Min 0.9103 0.9001 0.9018 0.9017 0.9024 0.8973 0.8974 0.8964
TABLE C.1: KPSmin : 1− R2 for different PLS components configura-
tions in 1_1 ngram_combination.
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Features 1C 2C 3C 4C 5C 10C 20C 50C
400 0.9222 0.9113 0.9169 0.9393 0.9404 0.9485 0.9501 0.9501
350 0.914 0.8971 0.9015 0.9156 0.9158 0.9213 0.9222 0.922
300 0.908 0.8954 0.8969 0.9113 0.9112 0.9139 0.9154 0.9154
250 0.9102 0.8988 0.8998 0.9101 0.912 0.915 0.9158 0.9156
240 0.897 0.8874 0.8874 0.8982 0.8973 0.8998 0.9012 0.9041
230 0.9012 0.8903 0.8888 0.8983 0.8977 0.8999 0.9004 0.9018
220 0.9053 0.8946 0.8936 0.9017 0.9004 0.9013 0.9009 0.9012
210 0.9068 0.8996 0.8993 0.9119 0.9123 0.909 0.9095 0.911
200 0.9115 0.9005 0.8991 0.9057 0.9065 0.9065 0.9075 0.9065
190 0.9093 0.8984 0.8977 0.9044 0.9084 0.9073 0.9082 0.909
180 0.905 0.8955 0.8932 0.9002 0.9019 0.901 0.9017 0.9018
170 0.9092 0.8993 0.8988 0.9064 0.9073 0.9043 0.9043 0.9058
160 0.9069 0.8976 0.8973 0.9019 0.9036 0.9028 0.9032 0.9042
150 0.922 0.9127 0.9112 0.9208 0.9216 0.9216 0.9231 0.9219
100 0.9207 0.9112 0.9095 0.9136 0.9139 0.9112 0.9113 0.9132
40 0.9421 0.9339 0.9331 0.9335 0.9359 0.9359 0.9359 0.9358
Min 0.897 0.8874 0.8874 0.8982 0.8973 0.8998 0.9004 0.9012
TABLE C.2: KPSmin : 1− R2 for different PLS components configura-
tions in 1_2 ngram_combination.
Features 1C 2C 3C 4C 5C 10C 20C 50C
400 0.9233 0.9159 0.9204 0.9446 0.9455 0.9576 0.958 0.958
350 0.9155 0.9033 0.9064 0.921 0.9214 0.9287 0.9278 0.928
300 0.9126 0.9016 0.9017 0.9149 0.9136 0.9176 0.9189 0.9208
250 0.9085 0.8984 0.8975 0.9057 0.9048 0.9075 0.9082 0.9066
240 0.8991 0.891 0.8873 0.8964 0.8954 0.8982 0.8985 0.8992
230 0.9067 0.8992 0.896 0.9057 0.9058 0.908 0.9072 0.9092
220 0.9099 0.9008 0.8972 0.9037 0.903 0.9023 0.9022 0.9021
210 0.9048 0.8953 0.8936 0.9012 0.9009 0.8983 0.8979 0.8988
200 0.9023 0.8898 0.8884 0.8943 0.8927 0.8926 0.8926 0.8924
190 0.9031 0.8944 0.8929 0.8995 0.8987 0.897 0.8973 0.8989
180 0.9038 0.8945 0.8914 0.8973 0.8975 0.8937 0.8937 0.894
170 0.9079 0.8965 0.8949 0.9007 0.9003 0.9 0.8999 0.8992
160 0.9062 0.8973 0.8965 0.9012 0.9014 0.9025 0.902 0.9022
150 0.912 0.9043 0.901 0.908 0.9086 0.9085 0.9094 0.9097
100 0.9258 0.9165 0.9155 0.9178 0.9176 0.9151 0.914 0.9148
50 0.9487 0.9373 0.9353 0.9359 0.9368 0.935 0.9351 0.939
Min 0.8991 0.8898 0.8873 0.8943 0.8927 0.8926 0.8926 0.8924
TABLE C.3: KPSmin : 1− R2 for different PLS components configura-
tions in 1_3 ngram_combination.
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Features 1C 2C 3C 4C 5C 10C 20C 50C
400 0.9836 0.9878 0.9825 0.9962 0.9990 0.9999 1.0005 1.0034
350 0.9847 0.9824 0.9824 0.9875 0.9942 0.9963 0.9970 0.9960
300 0.9876 0.9874 0.9876 0.9970 0.9977 1.0020 1.0028 1.0034
250 0.9777 0.9746 0.9703 0.9805 0.9852 0.9863 0.9863 0.9876
240 0.9842 0.9759 0.9759 0.9810 0.9820 0.9853 0.9854 0.9865
230 0.9889 0.9844 0.9828 0.9908 0.9916 0.9941 0.9946 0.9944
220 0.9853 0.9790 0.9794 0.9872 0.9862 0.9922 0.9930 0.9924
210 0.9863 0.9846 0.9796 0.9814 0.9889 0.9916 0.9917 0.9902
200 0.9881 0.9879 0.9837 0.9868 0.9920 0.9960 0.9962 0.9986
190 0.9844 0.9760 0.9767 0.9778 0.9855 0.9863 0.9865 0.9870
180 0.9885 0.9823 0.9791 0.9808 0.9895 0.9917 0.9921 0.9920
170 0.9916 0.9870 0.9845 0.9938 0.9952 0.9999 1.0001 1.0018
160 0.9880 0.9775 0.9793 0.9790 0.9867 0.9900 0.9905 0.9942
150 0.9918 0.9853 0.9831 0.9844 0.9932 0.9968 0.9969 0.9970
100 0.9913 0.9741 0.9727 0.9740 0.9771 0.9795 0.9794 0.9768
50 0.9971 0.9840 0.9793 0.9827 0.9825 0.9822 0.9822 0.9812
Min 0.9777 0.9741 0.9703 0.9740 0.9771 0.9795 0.9794 0.9768
TABLE C.4: KPSmax : 1− R2 for different PLS components configura-
tions in 1_1 ngram_combination.
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Features 1C 2C 3C 4C 5C 10C 20C 50C
400 0.9735 0.9694 0.9706 0.9787 0.9839 0.9821 0.9849 0.9849
350 0.9692 0.9583 0.9557 0.9650 0.9660 0.9668 0.9682 0.9682
300 0.9675 0.9621 0.9535 0.9631 0.9655 0.9655 0.9696 0.9681
250 0.9699 0.9554 0.9495 0.9579 0.9571 0.9561 0.9583 0.9615
240 0.9673 0.9555 0.9506 0.9603 0.9580 0.9576 0.9594 0.9592
230 0.9740 0.9640 0.9583 0.9670 0.9688 0.9685 0.9698 0.9698
220 0.9749 0.9653 0.9604 0.9674 0.9678 0.9660 0.9684 0.9712
210 0.9698 0.9609 0.9557 0.9619 0.9621 0.9624 0.9636 0.9646
200 0.9714 0.9606 0.9589 0.9670 0.9648 0.9648 0.9662 0.9671
190 0.9785 0.9688 0.9647 0.9734 0.9742 0.9756 0.9767 0.9785
180 0.9787 0.9695 0.9677 0.9752 0.9746 0.9749 0.9754 0.9769
170 0.9798 0.9634 0.9636 0.9716 0.9718 0.9734 0.9756 0.9752
160 0.9774 0.9687 0.9652 0.9716 0.9720 0.9734 0.9730 0.9721
150 0.9799 0.9633 0.9634 0.9697 0.9682 0.9693 0.9706 0.9700
100 0.9764 0.9619 0.9607 0.9667 0.9666 0.9678 0.9692 0.9696
50 0.9898 0.9742 0.9710 0.9746 0.9765 0.9785 0.9783 0.9784
Min 0.9673 0.9554 0.9495 0.9579 0.9571 0.9561 0.9583 0.9592
TABLE C.5: KPSmax : 1− R2 for different PLS components configura-
tions in 1_2 ngram_combination.
Features 1C 2C 3C 4C 5C 10C 20C 50C
400 0.9650 0.9580 0.9536 0.9639 0.9693 0.9743 0.9786 0.9789
350 0.9695 0.9550 0.9500 0.9591 0.9643 0.9679 0.9763 0.9767
300 0.9653 0.9602 0.9544 0.9635 0.9685 0.9701 0.9778 0.9787
250 0.9692 0.9584 0.9549 0.9633 0.9630 0.9635 0.9669 0.9705
240 0.9658 0.9587 0.9542 0.9633 0.9626 0.9646 0.9666 0.9664
230 0.9701 0.9581 0.9535 0.9627 0.9655 0.9724 0.9758 0.9763
220 0.9743 0.9651 0.9627 0.9725 0.9739 0.9771 0.9826 0.9861
210 0.9709 0.9617 0.9590 0.9675 0.9719 0.9721 0.9775 0.9796
200 0.9750 0.9609 0.9581 0.9654 0.9664 0.9699 0.9724 0.9735
190 0.9803 0.9722 0.9686 0.9789 0.9818 0.9845 0.9867 0.9851
180 0.9803 0.9702 0.9690 0.9766 0.9781 0.9802 0.9841 0.9846
170 0.9759 0.9628 0.9611 0.9691 0.9696 0.9728 0.9748 0.9765
160 0.9771 0.9668 0.9652 0.9728 0.9712 0.9733 0.9734 0.9739
150 0.9810 0.9771 0.9688 0.9753 0.9773 0.9774 0.9792 0.9803
100 0.9797 0.9670 0.9641 0.9695 0.9707 0.9772 0.9790 0.9773
50 0.9899 0.9695 0.9680 0.9742 0.9772 0.9862 0.9866 0.9894
Min 0.9650 0.9550 0.9500 0.9591 0.9626 0.9635 0.9666 0.9664
TABLE C.6: KPSmax : 1− R2 for different PLS components configura-
tions in 1_3 ngram_combination.
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C.2 Multilayer Perceptron Results
C.2.1 Identity Activation Function
Features (2,100) (5,100) (7,100) (10,100) (15,100) (25,100)
500 0.9140 0.9132 0.9191 0.9163 0.9676 0.9162
450 0.9172 0.9384 0.9170 0.9124 0.9181 0.9136
400 0.9126 0.9132 0.9118 0.9157 0.9316 0.9153
350 0.9164 0.9196 0.9155 0.9189 0.9158 0.9139
300 0.9269 0.9163 0.9195 0.9189 0.9213 0.9216
250 0.9197 0.9309 0.9278 0.9599 0.9170 0.9180
240 0.9210 0.9372 0.9230 0.9070 0.9161 0.9208
230 0.9237 0.9192 0.9590 0.9221 0.9237 0.9224
220 0.9180 0.9221 0.9171 0.8973 0.9192 0.9211
210 0.9331 0.9215 0.9227 0.9183 0.9174 0.9220
200 0.9236 0.9365 0.9247 0.9025 0.9254 0.9111
190 0.9178 0.9169 0.9222 0.9385 0.9090 0.9215
180 0.9212 0.9234 0.9225 0.9833 0.9215 0.9234
170 0.9313 0.9332 0.9645 0.9160 0.9426 0.9267
160 0.9907 0.9317 0.9279 0.9280 0.9268 0.9309
150 0.9313 0.9329 0.9349 0.9344 0.9370 0.9362
100 0.9471 0.9369 0.9346 0.9427 0.9438 0.9423
50 0.9568 0.9727 0.9576 0.9582 0.9973 0.9579
Min 0.9126 0.9132 0.9118 0.8973 0.9090 0.9111
TABLE C.7: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_1 ngram_combination.
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Features (2,100) (5,100) (7,100) (10,100) (15,100) (25,100)
500 0.9051 0.9022 0.9006 0.9056 0.9471 0.9009
450 0.9100 0.9249 0.9017 0.8965 0.9044 0.9041
400 0.9110 0.9023 0.9129 0.9129 0.9228 0.9103
350 0.9075 0.9140 0.9127 0.9054 0.9015 0.9080
300 0.9131 0.9198 0.9014 0.9162 0.9094 0.9114
250 0.9095 0.9575 0.9232 0.9276 0.9136 0.9147
240 0.9069 0.9930 0.9097 0.9164 0.9043 0.9072
230 0.9093 0.9181 0.9813 0.9020 0.9105 0.9111
220 0.9126 0.9152 0.9107 0.9059 0.9180 0.9164
210 0.9165 0.9144 0.9162 0.9140 0.9148 0.9179
200 0.9197 0.9318 0.9235 0.8985 0.9203 0.9070
190 0.9213 0.9306 0.9269 0.9286 0.9114 0.9215
180 0.9184 0.9552 0.9224 0.9351 0.9182 0.9195
170 0.9218 0.9240 0.9169 0.9098 0.9242 0.9216
160 0.9493 0.9217 0.9220 0.9395 0.9226 0.9245
150 0.9282 0.9286 0.9316 0.9304 0.9323 0.9331
100 0.9459 0.9338 0.9289 0.9358 0.9365 0.9363
50 0.9590 0.9551 0.9577 0.9583 0.9632 0.9577
Min 0.9051 0.9022 0.9006 0.8965 0.9015 0.9009
TABLE C.8: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_2 ngram_combination.
Features (2,100) (5,100) (7,100) (10,100) (15,100) (25,100)
500 0.9084 0.9111 0.9085 0.9068 0.9652 0.9074
450 0.9069 0.9271 0.9040 0.9067 0.9068 0.9083
400 0.9056 0.9073 0.9113 0.9129 0.9177 0.9103
350 0.9086 0.9122 0.9128 0.9133 0.9095 0.9100
300 0.9129 0.9168 0.9107 0.9127 0.9127 0.9109
250 0.9078 0.9179 0.9171 0.9197 0.9096 0.9127
240 0.9056 0.9363 0.9112 0.8903 0.9048 0.9055
230 0.9112 0.9130 0.9874 0.9078 0.9124 0.9131
220 0.9159 0.9162 0.8965 0.9072 0.9143 0.9135
210 0.8985 0.9142 0.9139 0.9122 0.9076 0.9154
200 0.9115 0.9260 0.9166 0.8962 0.9174 0.9024
190 0.9148 0.9092 0.9381 0.9233 0.8931 0.9165
180 0.9175 0.9501 0.9307 0.9354 0.9164 0.9183
170 0.9198 0.9233 0.9259 0.9275 0.9383 0.9210
160 0.9905 0.9228 0.9200 0.9177 0.9141 0.9203
150 0.9260 0.9222 0.9267 0.9251 0.9267 0.9259
100 0.9429 0.9350 0.9334 0.9400 0.9416 0.9421
50 0.9567 0.9583 0.9573 0.9600 0.9621 0.9582
Min 0.8985 0.9073 0.8965 0.8903 0.8931 0.9024
TABLE C.9: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_3 ngram_ombination.
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Features (2,50) (5,50) (7,25) (10,100) (15,25) (25,25)
500 1.0267 1.0347 1.0017 1.0795 1.0446 1.0220
450 1.0039 1.0508 1.0034 1.0497 1.0127 1.0346
400 1.0346 1.0359 1.0119 1.0608 1.0151 1.0056
350 1.0246 1.0556 1.0557 0.9999 0.9922 1.0397
300 1.0245 1.0585 1.0506 1.0920 1.0377 1.1117
250 1.0227 1.0301 1.0049 0.9891 1.0071 1.0115
240 1.0185 1.0159 1.0091 1.0083 1.0216 1.0005
230 1.0287 1.0272 1.0212 1.0318 0.9904 1.1888
220 1.0435 1.0358 1.0296 1.0235 0.9823 0.9885
210 1.0020 1.0137 1.0269 1.0571 1.0231 1.0159
200 1.0197 1.0046 1.0125 1.0095 0.9968 1.0144
190 1.0452 1.0277 0.9895 1.0271 1.0077 1.0437
180 1.0391 1.0267 1.0356 1.0124 1.0002 0.9883
170 1.0301 0.9958 1.0126 1.0783 1.0029 1.0167
160 1.0148 1.0312 1.0166 1.0278 1.0112 1.0214
150 1.0139 1.0328 0.9943 1.0427 1.0155 1.0338
100 1.0255 1.0230 1.0224 1.0254 1.0108 1.0035
50 1.0150 1.0024 1.0039 1.0173 1.0195 1.0028
Min 1.0020 0.9958 0.9895 0.9891 0.9823 0.9883
TABLE C.10: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_1 ngram_combination.
Features (2,50) (5,50) (7,25) (10,100) (15,25) (25,25)
500 1.0073 1.0309 0.9955 1.0594 1.0188 1.0333
450 1.0551 1.0543 1.0025 1.0529 1.0144 1.0644
400 0.9920 1.0260 1.0006 1.0390 1.0110 1.0016
350 1.0126 1.0525 1.0000 0.9994 0.9817 0.9894
300 1.0174 1.0176 1.0182 1.0495 1.0001 1.1041
250 1.0134 0.9884 0.9884 0.9935 1.0033 1.0079
240 1.0086 1.0033 1.0126 0.9668 1.0189 1.0058
230 1.0256 0.9919 1.0085 1.0118 1.0065 1.1429
220 1.0273 1.0146 1.0127 1.0075 1.0289 1.0231
210 1.0144 1.0096 1.0245 1.0173 1.0383 1.0042
200 1.0460 0.9896 0.9997 1.0292 1.0048 1.0251
190 1.0551 1.0043 0.9785 1.0251 1.0174 0.9865
180 1.0262 0.9746 0.9999 1.0095 1.0223 0.9879
170 1.0240 0.9981 1.0112 1.0101 1.0007 0.9920
160 1.0112 1.0278 1.0205 1.0175 1.0244 1.0122
150 1.0137 1.0250 1.0235 1.0200 0.9966 1.0770
100 0.9992 1.0217 1.0185 1.0163 1.0655 0.9942
50 1.0107 0.9981 0.9856 1.0095 1.0119 1.0088
Min 0.9920 0.9746 0.9785 0.9668 0.9817 0.9865
TABLE C.11: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_2 ngram_combination.
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Features (2,50) (5,50) (7,25) (10,100) (15,25) (25,25)
500 0.9794 1.0268 0.9988 1.0737 1.0264 1.0214
450 1.0199 1.0743 1.0100 1.0431 1.0138 1.0570
400 1.0189 1.0080 1.0114 1.0391 1.0162 1.0073
350 1.0180 1.0444 0.9970 1.0170 0.9850 1.0103
300 1.0250 1.0246 1.0164 1.0580 1.0287 1.0573
250 0.9995 1.0210 0.9854 1.0184 0.9970 1.0190
240 1.0151 1.0049 1.0216 0.9734 1.0128 1.0072
230 1.0018 1.0106 1.0147 0.9997 1.0020 1.0900
220 1.0287 1.0258 1.0411 0.9917 1.0117 1.0062
210 0.9994 1.0056 1.0282 1.0308 1.0138 1.0078
200 1.0299 1.0073 1.0038 1.0305 1.0006 1.0364
190 1.0308 1.0097 1.0002 1.0001 0.9910 1.0012
180 1.0297 0.9849 0.9890 1.0170 1.0309 0.9807
170 1.0117 1.0122 1.0176 1.0071 1.0017 1.0150
160 1.0101 1.0136 1.0353 1.0367 1.0167 1.0261
150 1.0219 1.0261 1.0149 1.0372 1.0036 1.0391
100 1.0180 1.0177 1.0581 1.0174 0.9940 1.0041
50 1.0116 0.9992 1.0121 1.0201 1.0102 1.0072
Min 0.9794 0.9849 0.9854 0.9734 0.9850 0.9807
TABLE C.12: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_3 ngram_combination.
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C.2.2 Logistic Activation Function
Features (2,75) (5,75) (7,75) (10,75) (15,75) (25,75)
500 0.9621 1.0000 1.0000 0.9713 1.0000 1.0000
450 0.9709 0.9567 1.0000 1.0000 1.0006 1.0000
400 0.9267 1.0000 1.0000 1.0000 1.0000 1.0000
350 1.0000 0.9297 0.9422 1.0000 1.0000 1.0000
300 0.9241 1.0000 1.0000 1.0000 1.0000 0.9450
250 1.0000 1.0000 1.0000 0.9190 1.0000 1.0000
240 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
230 0.9315 1.0000 1.0000 0.9359 1.0000 1.0000
220 0.9147 1.0000 0.9123 0.9382 1.0000 1.0000
210 0.9386 1.0000 1.0000 0.9268 1.0000 1.0000
200 0.9221 1.0000 1.0000 1.0000 0.9319 0.9359
190 1.0000 1.0000 0.9283 1.0000 1.0000 0.9363
180 0.9221 1.0000 0.9098 0.9163 1.0000 1.0000
170 1.0000 1.0000 0.9193 1.0000 1.0000 1.0000
160 0.9339 0.9333 1.0000 0.9267 1.0000 1.0000
150 1.0000 0.9428 0.9253 1.0000 1.0000 1.0000
100 0.9522 0.9286 0.9323 0.9211 1.0000 1.0000
50 1.0000 1.0000 0.9421 1.0000 1.0000 1.0000
Min 0.9147 0.9286 0.9098 0.9163 0.9319 0.9359
TABLE C.13: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_1 ngram_combination.
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Features (2,75) (5,75) (7,75) (10,75) (15,75) (25,75)
500 0.9665 1.0000 1.0000 0.9495 1.0000 1.0000
450 0.9469 0.9004 1.0000 1.0000 0.9784 1.0000
400 0.9168 1.0000 1.0000 1.0000 1.0000 1.0000
350 1.0000 0.9280 0.9154 1.0000 1.0000 1.0000
300 0.9294 1.0000 1.0000 1.0000 1.0000 0.9210
250 1.0000 1.0000 1.0000 0.9065 1.0000 1.0000
240 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
230 0.9097 1.0000 1.0000 0.9086 1.0000 1.0000
220 0.9080 1.0000 0.9145 0.9076 1.0000 1.0000
210 0.9121 1.0000 1.0000 0.9165 1.0000 1.0000
200 0.9112 1.0000 1.0000 1.0000 0.9288 0.9358
190 1.0000 1.0000 0.9024 1.0000 1.0000 0.9267
180 0.9118 1.0000 0.9008 0.9176 1.0000 1.0000
170 1.0000 1.0000 0.9126 1.0000 1.0000 1.0000
160 1.0000 0.9090 1.0000 0.9111 1.0000 1.0000
150 1.0000 0.9185 0.9180 1.0000 1.0000 1.0000
100 0.9344 0.9154 0.9103 0.9142 1.0000 1.0000
50 1.0000 1.0000 0.9414 1.0000 1.0000 1.0000
Min 0.9080 0.9004 0.9008 0.9065 0.9288 0.9210
TABLE C.14: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_2 ngram_combination.
Features (2,75) (5,75) (7,75) (10,75) (15,75) (25,75)
500 0.9618 1.0000 1.0000 0.9466 1.0000 1.0000
450 0.9719 0.9097 1.0000 1.0000 0.9697 1.0000
400 0.9419 1.0000 1.0000 1.0000 1.0000 1.0000
350 1.0000 0.9248 0.9089 1.0000 1.0000 1.0000
300 0.9458 1.0000 1.0000 1.0000 1.0000 0.9458
250 1.0000 1.0000 1.0000 0.9170 1.0000 1.0000
240 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
230 0.9146 1.0000 1.0000 0.9153 1.0000 1.0000
220 0.9217 1.0000 0.9108 0.9040 1.0000 1.0000
210 0.9069 1.0000 1.0000 0.9127 1.0000 1.0000
200 0.9118 1.0000 1.0000 1.0000 0.9179 0.9052
190 1.0000 1.0000 0.8965 1.0000 1.0000 0.9257
180 0.8951 1.0000 0.9001 0.9075 1.0000 1.0000
170 1.0000 1.0000 0.9239 1.0000 1.0000 1.0000
160 1.0000 0.9143 1.0000 0.9249 1.0000 1.0000
150 1.0000 0.9130 0.9147 1.0000 1.0000 1.0000
100 0.9362 0.9236 0.9239 0.9220 1.0000 1.0000
50 1.0000 1.0000 0.9532 1.0000 1.0000 1.0000
Min 0.8951 0.9097 0.8965 0.9040 0.9179 0.9052
TABLE C.15: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_3 ngram_combination.
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Features (2,100) (5,50) (7,50) (10,50) (15,25) (25,25)
500 1.0743 0.9999 0.9999 0.9998 0.9999 1.0868
450 1.0523 1.0542 0.9999 0.9999 1.0557 0.9999
400 1.0601 0.9999 0.9999 0.9999 0.9999 0.9999
350 0.9999 1.0725 1.0597 0.9999 0.9999 0.9999
300 1.0458 0.9999 0.9999 0.9999 0.9999 1.0005
250 0.9999 0.9999 0.9999 0.9860 0.9999 0.9999
240 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
230 0.9990 0.9999 0.9999 1.0106 0.9999 0.9999
220 1.0549 0.9999 1.0138 1.0105 0.9999 0.9999
210 1.0366 0.9999 0.9999 1.0306 0.9999 0.9999
200 1.0462 0.9999 0.9999 0.9999 1.0502 1.0118
190 0.9999 0.9999 0.9895 0.9999 0.9999 1.0472
180 1.0109 0.9999 1.0751 1.0376 0.9999 0.9999
170 0.9999 0.9999 1.0449 0.9999 0.9999 0.9999
160 1.0366 1.0389 0.9999 1.0643 0.9999 0.9999
150 0.9999 1.0399 1.0185 0.9999 0.9999 0.9999
100 1.0420 1.0124 1.0353 1.0052 0.9999 0.9999
50 0.9999 0.9999 1.0054 0.9999 0.9999 0.9999
Min 0.9990 0.9999 0.9895 0.9860 0.9999 0.9999
TABLE C.16: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_1 ngram_combination.
Features (2,100) (5,50) (7,50) (10,50) (15,25) (25,25)
500 1.0699 0.9999 0.9999 1.0427 0.9999 0.9999
450 1.0213 0.9961 0.9999 0.9999 1.0458 0.9999
400 1.0155 0.9999 0.9999 0.9999 0.9999 0.9999
350 0.9999 1.0375 1.0198 0.9999 0.9999 0.9999
300 1.0317 0.9999 0.9999 0.9999 0.9999 0.9939
250 0.9999 0.9999 0.9999 0.9800 0.9999 0.9999
240 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
230 0.9916 0.9999 0.9999 1.0661 0.9999 0.9999
220 1.0363 0.9999 0.9689 1.0264 0.9999 0.9999
210 1.0037 0.9999 0.9999 0.9985 0.9999 0.9999
200 1.0143 0.9999 0.9999 0.9999 1.0307 1.0374
190 0.9999 0.9999 1.0195 0.9999 0.9999 0.9842
180 0.9922 0.9999 1.0315 1.0083 0.9999 0.9999
170 0.9999 0.9999 1.0521 0.9999 0.9999 0.9999
160 0.9999 1.0238 0.9999 1.0560 0.9999 0.9999
150 0.9999 1.0431 0.9895 0.9999 0.9999 0.9999
100 1.0557 0.9852 1.0226 0.9916 0.9999 0.9999
50 0.9999 0.9999 1.0191 0.9999 0.9999 0.9999
Min 0.9916 0.9852 0.9689 0.9800 0.9999 0.9842
TABLE C.17: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_2 ngram_combination.
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Features (2,100) (5,50) (7,50) (10,50) (15,25) (25,25)
500 1.1069 0.9999 0.9999 0.9971 0.9999 0.9999
450 1.0484 0.9936 0.9999 0.9999 1.0558 0.9999
400 1.0381 0.9999 0.9999 0.9999 0.9999 0.9999
350 0.9999 1.0324 1.0110 0.9999 0.9999 0.9999
300 1.0419 0.9999 0.9999 0.9999 0.9999 0.9944
250 0.9999 0.9999 0.9999 1.0346 0.9999 0.9999
240 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
230 1.0031 0.9999 0.9999 1.0201 0.9999 0.9999
220 1.0586 0.9999 0.9834 1.0299 0.9999 0.9999
210 1.0215 0.9999 0.9999 1.0203 0.9999 0.9999
200 1.0034 0.9999 0.9999 0.9999 1.0253 1.0068
190 0.9999 0.9999 1.0264 0.9999 0.9999 1.0391
180 0.9945 0.9999 1.0356 0.9945 0.9999 0.9999
170 0.9999 0.9999 1.0728 0.9999 0.9999 0.9999
160 0.9999 1.0327 0.9999 1.0450 0.9999 0.9999
150 0.9999 1.0744 0.9948 0.9999 0.9999 0.9999
100 1.0263 1.0002 1.0554 1.0088 0.9999 0.9999
50 0.9999 0.9999 1.0033 0.9999 0.9999 0.9999
Min 0.9945 0.9936 0.9834 0.9945 0.9999 0.9944
TABLE C.18: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_3 ngram_combination.
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C.2.3 Hyperbolic Tangent Activation Function
Features (2,50) (5,50) (7,75) (10,50) (15,50) (25,10)
500 0.9406 1.0000 1.0000 1.0000 1.0000 1.0000
450 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
400 1.0000 1.0000 1.0000 0.9316 1.0000 1.0000
350 1.0000 0.9559 1.0000 1.0000 1.0000 1.0000
300 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
250 0.9442 1.0000 1.0000 1.0000 1.0000 1.0000
240 1.0000 1.0000 1.0000 0.9698 1.0000 1.0000
230 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
220 0.9333 1.0000 1.0000 0.9556 1.0000 1.0000
210 1.0000 1.0000 1.0000 1.0000 0.9298 1.0000
200 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
190 0.9388 1.0000 1.0000 1.0000 1.0000 1.0000
180 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
170 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
160 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
150 1.0000 1.0000 1.0000 1.0000 0.9937 1.0000
100 1.0000 1.0000 1.0000 0.9582 1.0000 1.0000
50 1.0000 1.0000 1.0000 0.9761 1.0000 1.0000
Min 0.9333 0.9559 1.0000 0.9316 0.9298 1.0000
TABLE C.19: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_1 ngram_combination.
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Features (2,50) (5,50) (7,75) (10,50) (15,50) (25,10)
500 0.9306 1.0000 1.0000 1.0000 1.0000 1.0000
450 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
400 1.0000 1.0000 1.0000 0.9477 1.0000 1.0000
350 1.0000 0.9344 1.0000 1.0000 1.0000 1.0000
300 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
250 0.9388 1.0000 1.0000 1.0000 1.0000 1.0000
240 1.0000 1.0000 1.0000 0.9610 1.0000 1.0000
230 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
220 0.9256 1.0000 1.0000 0.9235 1.0000 1.0000
210 1.0000 1.0000 0.9754 1.0000 0.9226 1.0000
200 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
190 0.9396 1.0000 1.0000 1.0000 1.0000 1.0000
180 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
170 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
160 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
150 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
100 1.0000 1.0000 1.0000 0.9486 1.0000 1.0000
50 1.0000 1.0000 1.0000 0.9956 1.0000 1.0000
Min 0.9256 0.9344 0.9754 0.9235 0.9226 1.0000
TABLE C.20: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_2 ngram_combination.
Features (2,50) (5,50) (7,75) (10,50) (15,50) (25,10)
500 0.9266 1.0000 1.0000 1.0000 1.0000 1.0000
450 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
400 1.0000 1.0000 1.0000 0.9335 1.0000 1.0000
350 1.0000 0.9324 1.0000 1.0000 1.0000 1.0000
300 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
250 0.9517 1.0000 1.0000 1.0000 1.0000 1.0000
240 1.0000 1.0000 1.0000 0.9268 1.0000 1.0000
230 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
220 0.9303 1.0000 1.0000 0.9264 1.0000 1.0000
210 1.0000 1.0000 0.9786 1.0000 0.9259 1.0000
200 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
190 0.9368 1.0000 1.0000 1.0000 1.0000 1.0000
180 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
170 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
160 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
150 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
100 1.0000 1.0000 0.9726 0.9527 1.0000 1.0000
50 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
Min 0.9266 0.9324 0.9726 0.9264 0.9259 1.0000
TABLE C.21: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_3 ngram_combination.
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Features (2,50) (5,10) (7,50) (10,10) (15,10) (25,10)
500 1.0355 0.9999 0.9999 0.9999 0.9999 0.9999
450 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
400 0.9999 0.9999 0.9999 1.0475 0.9999 0.9999
350 0.9999 0.9981 0.9999 0.9999 0.9999 0.9999
300 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
250 1.0544 0.9999 0.9999 0.9999 0.9999 0.9999
240 0.9999 0.9999 0.9999 1.0034 0.9999 0.9999
230 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
220 1.0582 0.9999 0.9999 1.0163 0.9999 0.9999
210 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
200 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
190 1.0729 0.9999 0.9999 0.9999 0.9999 0.9999
180 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
170 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
160 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
150 0.9999 0.9999 0.9999 0.9999 1.0914 0.9999
100 0.9999 0.9999 0.9999 1.0494 0.9999 0.9999
50 0.9999 0.9999 0.9999 0.9845 0.9999 0.9999
Min 0.9999 0.9981 0.9999 0.9845 0.9999 0.9999
TABLE C.22: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_1 ngram_combination.
Features (2,50) (5,10) (7,50) (10,10) (15,10) (25,10)
500 1.0342 0.9999 0.9999 0.9999 0.9999 0.9999
450 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
400 0.9999 0.9999 0.9999 1.0279 0.9999 0.9999
350 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
300 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
250 1.0330 0.9999 0.9999 0.9999 0.9999 0.9999
240 0.9999 0.9999 0.9999 1.0193 0.9999 0.9999
230 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
220 1.0321 0.9999 0.9999 1.0392 0.9999 0.9999
210 0.9999 0.9999 0.9965 0.9999 0.9945 0.9999
200 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
190 1.0847 0.9999 0.9999 0.9999 0.9999 0.9999
180 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
170 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
160 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
150 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
100 0.9999 0.9999 0.9999 1.0199 0.9999 0.9999
50 0.9999 0.9999 0.9999 1.0011 0.9999 0.9999
Min 0.9999 0.9999 0.9965 0.9999 0.9945 0.9999
TABLE C.23: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_2 ngram_combination.
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Features (2,50) (5,10) (7,50) (10,10) (15,10) (25,10)
500 1.0303 0.9999 0.9999 0.9999 0.9999 0.9999
450 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
400 0.9999 0.9999 0.9999 1.0280 0.9999 0.9999
350 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
300 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
250 0.9879 0.9999 0.9999 0.9999 0.9999 0.9999
240 0.9999 0.9999 0.9999 1.0038 0.9999 0.9999
230 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
220 1.0215 0.9999 0.9999 1.0322 0.9999 0.9999
210 0.9999 0.9999 1.0068 0.9999 0.9999 0.9999
200 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
190 1.0846 0.9999 0.9999 0.9999 0.9999 0.9999
180 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
170 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
160 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
150 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
100 0.9999 0.9999 1.0108 1.0138 0.9999 0.9999
50 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
Min 0.9879 0.9999 0.9999 0.9999 0.9999 0.9999
TABLE C.24: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_3 ngram_combination.
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C.2.4 Rectified Linear Unit Activation Function
Features (2,100) (5,100) (7,100) (10,100) (15,100) (25,100)
500 1.0000 0.9179 1.0000 1.0000 0.9419 1.0000
450 1.0000 0.9604 1.0000 1.0000 1.0000 0.9128
400 1.0000 0.9123 0.9176 0.9183 1.0000 0.9172
350 0.9140 0.9200 1.0000 0.9994 1.0000 1.0000
300 0.9203 1.0000 1.0000 1.0000 0.9188 0.9352
250 1.0000 1.0000 0.9202 1.0000 0.9153 0.9112
240 0.9256 1.0000 1.0000 1.0000 0.9143 0.9180
230 1.0000 0.9192 1.0000 0.9147 1.0000 0.9172
220 0.9198 0.9205 1.0000 1.0007 0.9855 1.0000
210 1.0000 1.0000 0.9209 0.9259 0.9292 0.9197
200 1.0000 0.9892 0.9209 1.0000 1.0000 0.9209
190 1.0000 1.0000 1.0000 1.0000 0.9134 1.0000
180 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
170 0.9303 1.0000 1.0000 0.9417 1.0000 0.9950
160 1.0000 0.9300 1.0000 1.0000 1.0000 0.9127
150 0.9275 1.0000 1.0000 0.9499 0.9353 1.0000
100 0.9448 1.0000 0.9435 0.9342 0.9435 0.9438
50 1.0000 0.9476 1.0000 1.0000 1.0000 0.9561
Min 0.9140 0.9123 0.9176 0.9147 0.9134 0.9112
TABLE C.25: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_1 ngram_combination.
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Features (2,100) (5,100) (7,100) (10,100) (15,100) (25,100)
500 0.9085 0.9071 1.0000 1.0000 0.9134 1.0000
450 1.0000 0.9566 1.0000 1.0000 1.0000 0.9048
400 1.0000 0.8944 0.9148 0.9142 1.0000 0.9104
350 0.9056 0.9165 1.0000 1.0000 1.0000 1.0000
300 0.9187 1.0000 1.0000 1.0000 0.9081 0.9443
250 1.0000 1.0000 0.9073 1.0000 0.9145 0.9107
240 0.9091 1.0000 1.0000 1.0000 0.9019 0.9078
230 1.0000 0.9109 1.0000 0.9122 1.0000 0.9097
220 0.9138 0.9124 1.0000 1.0032 1.0000 1.0000
210 1.0000 1.0000 0.9136 0.9132 0.9124 0.9008
200 1.0000 1.0000 0.9065 1.0000 1.0000 0.9148
190 1.0000 1.0000 1.0000 1.0000 0.9121 1.0000
180 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
170 0.9202 1.0000 1.0000 0.9256 1.0000 1.0000
160 1.0000 0.9170 1.0000 1.0000 1.0000 0.9071
150 0.9224 1.0000 1.0000 0.9824 0.9297 1.0000
100 0.9382 1.0000 0.9349 0.9172 0.9364 0.9354
50 1.0000 0.9575 1.0000 1.0000 1.0000 0.9557
Min 0.9056 0.8944 0.9065 0.9122 0.9019 0.9008
TABLE C.26: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_2 ngram_combination.
Features (2,100) (5,100) (7,100) (10,100) (15,100) (25,100)
500 0.9314 0.9112 1.0000 1.0000 0.9422 1.0000
450 1.0000 0.9451 1.0000 1.0000 1.0000 0.9077
400 1.0000 0.9127 0.9187 0.9165 1.0000 0.9096
350 0.9096 0.9099 1.0000 1.0057 1.0000 1.0000
300 0.9208 1.0000 1.0000 1.0000 0.9076 0.9549
250 1.0000 1.0000 0.9013 1.0000 0.9068 0.9035
240 0.9134 1.0000 1.0000 1.0000 0.8976 0.9029
230 1.0000 0.9083 1.0000 0.9010 1.0000 0.9085
220 0.9150 0.9145 1.0000 1.0000 1.0000 1.0000
210 1.0000 1.0000 0.9135 0.9109 0.9110 0.9337
200 1.0000 1.0000 0.9124 1.0000 1.0000 0.9149
190 1.0000 1.0000 1.0000 1.0000 0.8934 1.0000
180 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
170 0.9234 1.0000 1.0000 0.9325 1.0000 1.0000
160 1.0000 0.9198 1.0000 1.0000 1.0000 0.9084
150 0.9219 1.0000 1.0000 0.9236 0.9247 1.0000
100 0.9401 1.0000 0.9544 0.9246 0.9366 0.9412
50 1.0000 0.9514 1.0000 1.0000 1.0000 0.9595
Min 0.9096 0.9083 0.9013 0.9010 0.8934 0.9029
TABLE C.27: KPSmin : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_3 ngram_combination.
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Features (2,25) (5,25) (7,25) (10,25) (15,25) (25,100)
500 0.9999 0.9844 0.9999 0.9999 1.0187 0.9999
450 0.9999 1.0336 0.9999 0.9999 0.9999 1.1220
400 0.9999 1.0193 1.0294 0.9892 0.9999 1.0655
350 1.0050 1.0753 0.9999 1.0010 0.9999 0.9999
300 1.0510 0.9999 0.9999 0.9999 1.0138 1.0164
250 0.9999 0.9999 1.0319 0.9999 1.0477 1.0460
240 0.9948 0.9999 0.9999 0.9999 1.0030 1.0515
230 0.9999 0.9955 0.9999 1.0211 0.9999 1.0724
220 0.9996 1.0171 0.9999 1.0060 1.0138 0.9999
210 0.9999 0.9999 1.0187 1.0101 1.0173 1.0275
200 0.9999 1.0013 1.0253 0.9999 0.9999 1.0960
190 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
180 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
170 0.9910 0.9999 0.9999 0.9966 0.9999 1.0018
160 0.9999 1.0101 0.9999 0.9999 0.9999 1.0148
150 1.0263 0.9999 0.9999 0.9907 1.0109 0.9999
100 0.9975 0.9999 1.0222 0.9998 0.9869 1.0245
50 0.9999 1.0167 0.9999 0.9999 0.9999 1.0221
Min 0.9910 0.9844 0.9999 0.9892 0.9869 0.9999
TABLE C.28: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_1 ngram_combination.
Features (2,25) (5,25) (7,25) (10,25) (15,25) (25,100)
500 1.0088 1.0375 0.9999 0.9999 1.0125 0.9999
450 0.9999 0.9899 0.9999 0.9999 0.9999 1.1036
400 0.9999 1.0036 1.0046 0.9770 0.9999 1.0538
350 1.0056 1.0373 0.9999 0.9999 0.9999 0.9999
300 1.0168 0.9999 0.9999 0.9999 1.0247 0.9811
250 0.9999 0.9999 1.0313 0.9999 1.0655 0.9710
240 0.9906 0.9999 0.9999 0.9999 1.0248 1.0207
230 0.9999 0.9892 0.9999 1.0407 0.9999 1.0308
220 1.0035 1.0027 0.9999 1.0069 0.9999 0.9999
210 0.9999 0.9999 1.0281 1.0144 1.0226 1.0035
200 0.9999 0.9999 1.0117 0.9999 0.9999 1.0605
190 0.9999 0.9999 0.9999 0.9999 1.0096 0.9999
180 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
170 1.0078 0.9999 0.9999 1.0100 0.9999 0.9999
160 0.9999 1.0111 0.9999 0.9999 0.9999 1.0138
150 1.0167 0.9999 0.9999 1.0265 1.0121 0.9999
100 1.0116 0.9999 1.0056 1.0103 0.9855 1.0157
50 0.9999 1.0202 0.9999 0.9999 0.9999 1.0121
Min 0.9906 0.9892 0.9999 0.9770 0.9855 0.9710
TABLE C.29: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_2 ngram_combination.
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Features (2,25) (5,25) (7,25) (10,25) (15,25) (25,100)
500 1.0052 1.0129 0.9999 0.9999 1.0211 0.9999
450 0.9999 0.9868 0.9999 0.9999 0.9999 1.0522
400 0.9999 1.0170 1.0341 1.0017 0.9999 1.0469
350 1.0082 1.0115 0.9999 1.0020 0.9999 0.9999
300 1.0383 0.9999 0.9999 0.9999 1.0182 0.9993
250 0.9999 0.9999 1.0157 0.9999 1.0500 1.0226
240 0.9963 0.9999 0.9999 0.9999 1.0029 1.0208
230 0.9999 0.9864 0.9999 1.0404 0.9999 1.0462
220 1.0146 0.9973 0.9999 0.9999 0.9999 0.9999
210 0.9999 0.9999 1.0271 1.0063 1.0139 0.9979
200 0.9999 0.9999 0.9654 0.9999 0.9999 1.0603
190 0.9999 0.9999 0.9999 0.9999 0.9965 0.9999
180 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999
170 0.9948 0.9999 0.9999 1.0172 0.9999 0.9999
160 0.9999 0.9986 0.9999 0.9999 0.9999 1.0245
150 0.9974 0.9999 0.9999 0.9932 1.0201 0.9999
100 1.0207 0.9999 1.0156 1.0078 0.9915 1.0198
50 0.9999 1.0171 0.9999 0.9999 0.9999 1.0121
Min 0.9948 0.9864 0.9654 0.9932 0.9915 0.9979
TABLE C.30: KPSmax : 1− R2 for the best MLP (neurons, epochs) and
α = 1x10−3 configurations in 1_3 ngram_combination.
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Appendix D
Problematic Cases in Clinical Trials
D.1 Response Variables in CT Problematic Cases
In this Appendix we are going to show the KPS min, and max response variables
related to the problematic cases in clinical trials.
• NCT00001880: [0, 40]
• NCT00001880: [0, 40]
• NCT00002628: [0, 20]
• NCT00010010: [90, 100]
• NCT00034827: [10, 40]
• NCT00079625: [10, 20]
• NCT00130507: [0, 60]
• NCT00131963: [0, 40]
• NCT00135018: [0, 0]
• NCT00162929: [0, 40]
• NCT00195013: [100, 100]
• NCT00197522: [0, 40]
• NCT00239343: [30, 60]
• NCT00263705: [30, 40]
• NCT00264082: [10, 40]
• NCT00295620: [0, 40]
• NCT00307229: [0, 40]
• NCT00309530: [0, 40]
• NCT00309543: [0, 40]
• NCT00309933: [10, 20]
• NCT00348699: [10, 40]
• NCT00412022: [0, 40]
• NCT00429507: [30, 40]
• NCT00509691: [0, 0]
• NCT00516269: [10, 20]
• NCT00539968: [50, 60]
• NCT00578006: [0, 40]
• NCT00637325: [0, 40]
• NCT00707707: [0, 40]
• NCT00713141: [30, 40]
• NCT00759642: [50, 60]
• NCT00774878: [0, 40]
• NCT00811369: [0, 40]
• NCT00824733: [0, 0]
• NCT00825734: [50, 60]
• NCT00826085: [0, 40]
• NCT00841828: [0, 0]
• NCT00863122: [60, 60]
• NCT00896727: [30, 40]
• NCT00923936: [10, 20]
• NCT00942331: [0, 0]
• NCT00949013: [30, 40]
• NCT00951574: [0, 40]
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• NCT00967577: [0, 40]
• NCT00968968: [0, 40]
• NCT00997529: [0, 0]
• NCT01077453: [0, 0]
• NCT01091883: [10, 10]
• NCT01105650: [50, 50]
• NCT01132560: [0, 0]
• NCT01159067: [0, 40]
• NCT01190345: [0, 0]
• NCT01198158: [0, 0]
• NCT01306045: [30, 40]
• NCT01315119: [0, 0]
• NCT01320592: [0, 20]
• NCT01320787: [0, 0]
• NCT01351909: [0, 0]
• NCT01384253: [0, 20]
• NCT01396655: [10, 20]
• NCT01432002: [30, 40]
• NCT01483001: [100, 100]
• NCT01495663: [0, 20]
• NCT01503372: [50, 60]
• NCT01513356: [50, 60]
• NCT01530373: [0, 40]
• NCT01534455: [0, 60]
• NCT01596647: [0, 40]
• NCT01688479: [0, 20]
• NCT01698281: [0, 40]
• NCT01716468: [30, 40]
• NCT01771666: [0, 0]
• NCT01805908: [0, 40]
• NCT01814865: [30, 40]
• NCT01823991: [0, 0]
• NCT01861509: [0, 40]
• NCT01866670: [0, 20]
• NCT01876238: [0, 20]
• NCT01895491: [0, 40]
• NCT01912963: [0, 0]
• NCT01927081: [0, 50]
• NCT01937507: [0, 20]
• NCT01948128: [0, 40]
• NCT01957514: [0, 0]
• NCT02066532: [0, 0]
• NCT02089100: [30, 40]
• NCT02094742: [0, 40]
• NCT02097238: [0, 0]
• NCT02185352: [30, 30]
• NCT02203526: [50, 60]
• NCT02236000: [0, 60]
• NCT02276443: [0, 40]
• NCT02288169: [30, 40]
• NCT02324088: [10, 40]
• NCT02393794: [0, 60]
• NCT02424682: [50, 60]
• NCT02443467: [50, 60]
• NCT02453620: [0, 0]
• NCT02487979: [0, 0]
• NCT02496065: [0, 50]
• NCT02514083: [10, 20]
• NCT02524951: [0, 40]
• NCT02576665: [0, 0]
• NCT02587689: [0, 0]
• NCT02596373: [0, 20]
• NCT02619929: [0, 40]
• NCT02626039: [10, 40]
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• NCT02636582: [0, 0]
• NCT02645175: [0, 0]
• NCT02708511: [0, 40]
• NCT02721147: [0, 40]
• NCT02751710: [30, 40]
• NCT02768415: [0, 40]
• NCT02839954: [0, 0]
• NCT02850419: [0, 40]
• NCT02904135: [10, 20]
• NCT02947061: [0, 20]
• NCT02962947: [30, 40]
• NCT03032406: [50, 60]
• NCT03099200: [0, 40]
• NCT03265379: [0, 40]
• NCT03282825: [10, 20]
• NCT00002465: [30, 40]
• NCT00002529: [0, 0]
• NCT00002646: [0, 20]
• NCT00003012: [0, 40]
• NCT00003098: [0, 0]
• NCT00003418: [0, 40]
• NCT00014391: [10, 20]
• NCT00179348: [0, 40]
• NCT00217399: [30, 40]
• NCT00679783: [0, 40]
• NCT00841399: [30, 40]
• NCT00854789: [30, 40]
• NCT00929591: [0, 40]
• NCT01030250: [10, 20]
• NCT01277562: [10, 20]
• NCT01287624: [0, 60]
• NCT01387295: [0, 40]
• NCT01387373: [0, 40]
• NCT01535053: [10, 40]
• NCT01846650: [0, 20]
• NCT02348281: [0, 40]
• NCT02607215: [0, 40]
• NCT00124111: [0, 60]
• NCT00338728: [0, 60]
• NCT01835158: [0, 70]
• NCT02379247: [0, 60]
• NCT02416427: [0, 60]
• NCT02575781: [0, 60]
• NCT02774681: [0, 60]
• NCT02789657: [0, 60]
• NCT02867423: [0, 60]
• NCT01971515: [0, 60]
• NCT02341911: [0, 60]
• NCT02546934: [0, 60]
• NCT00114816: [0, 60]
• NCT00166543: [0, 60]
• NCT00176046: [0, 50]
• NCT00536081: [0, 60]
• NCT00593697: [0, 60]
• NCT00617942: [0, 60]
• NCT00820924: [0, 60]
• NCT00916877: [0, 60]
• NCT01110291: [0, 60]
• NCT01196455: [0, 60]
• NCT01240421: [0, 60]
• NCT01423695: [0, 60]
• NCT01686737: [0, 60]
• NCT01913067: [0, 60]
• NCT02244580: [0, 60]
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• NCT02437318: [0, 60]
• NCT02521441: [0, 60]
• NCT02522234: [0, 60]
• NCT02625441: [0, 60]
• NCT02783794: [0, 50]
• NCT00331097: [0, 60]
• NCT00516724: [0, 40]
• NCT02087592: [0, 50]
• NCT01368107: [30, 60]
• NCT02892734: [30, 60]
• NCT00325416: [30, 60]
• NCT01781468: [30, 60]
• NCT00005926: [50, 60]
• NCT00076609: [90, 100]
• NCT00140140: [50, 60]
• NCT00196859: [50, 60]
• NCT00256217: [50, 60]
• NCT00721630: [50, 60]
• NCT00944047: [50, 60]
• NCT01743560: [50, 60]
• NCT01823835: [50, 60]
• NCT02139358: [50, 60]
• NCT00491816: [50, 60]
• NCT00001302: [70, 70]
• NCT00003855: [50, 60]
• NCT00083304: [70, 70]
• NCT00106145: [50, 60]
• NCT00189644: [50, 60]
• NCT00194727: [0, 60]
• NCT00194766: [50, 60]
• NCT00270569: [70, 70]
• NCT00508443: [40, 40]
• NCT00519168: [70, 70]
• NCT00526617: [50, 60]
• NCT00581529: [70, 70]
• NCT00588640: [80, 80]
• NCT00603408: [0, 70]
• NCT00617968: [0, 60]
• NCT00636558: [0, 60]
• NCT00646633: [70, 70]
• NCT00779285: [60, 60]
• NCT00896324: [70, 70]
• NCT00934401: [60, 60]
• NCT01091168: [70, 70]
• NCT01095003: [70, 70]
• NCT01127074: [80, 80]
• NCT01339780: [70, 70]
• NCT01343459: [0, 60]
• NCT01433562: [80, 80]
• NCT01555944: [50, 50]
• NCT01777061: [0, 60]
• NCT01925651: [0, 60]
• NCT01929941: [0, 60]
• NCT01942980: [70, 70]
• NCT01953003: [70, 70]
• NCT01969448: [80, 80]
• NCT02050620: [0, 60]
• NCT02102568: [50, 60]
• NCT02159157: [80, 80]
• NCT02491892: [80, 80]
• NCT02581670: [0, 60]
• NCT02585362: [0, 60]
• NCT02738970: [50, 60]
• NCT02874430: [90, 100]
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• NCT02984683: [0, 60]
• NCT00002953: [0, 60]
• NCT00206440: [50, 60]
• NCT02866591: [0, 60]
• NCT02516540: [0, 50]
• NCT00123877: [70, 70]
• NCT00148876: [60, 60]
• NCT00155259: [70, 70]
• NCT00196820: [60, 60]
• NCT00226928: [70, 70]
• NCT00393783: [80, 80]
• NCT00515411: [70, 70]
• NCT00567554: [80, 80]
• NCT00929214: [70, 70]
• NCT00930475: [60, 60]
• NCT01172223: [80, 80]
• NCT01237457: [60, 60]
• NCT01598454: [50, 50]
• NCT02481128: [70, 70]
• NCT02617043: [70, 70]
• NCT03075072: [70, 70]
• NCT03110445: [70, 70]
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